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 Recent developments in the governance of research have recognised the part that 
communities can and should play in emergent and inventive research. It is now widely agreed that 
community engagement is essential in certain kinds of research – indeed, an ethical prerequisite – 
and that it is indispensable to the success of many health research projects. Unfortunately, as an 
ethical requirement, community engagement has sometimes been seen as a hurdle to jump over 
rather than as an integral part of the research process. At times, inadequate attention has been paid 
to how and when community engagement should be implemented and on the need to engage the 
community meaningfully and genuinely throughout the research process. This is concerning given 
that researchers and sponsors invest large sums of money in the development of a product, training 
on clinical procedures, facility designing and building, etc., and yet seem to have repeatedly ignored 
the importance of meaningful community engagement processes, often at great cost. 
 The aim of this study was to demonstrate, using the tenofovir trials that were stopped in 
both Cameroon and Cambodia in 2005, that inadequate community engagement might lead to 
significant scientific losses, whereas early, sustained and meaningful community engagement could 
prevent this from occurring. The study involved no human participants and used a case study design 
approach that was based on the secondary data analysis. The cases (Cameroon and Cambodia) for 
the study were chosen for a number of reasons, but perhaps most significant of these was that the 
Good Participatory Practice (GPP/AVAC) guidelines which set standard practices for stakeholder’s 
engagement in HIV vaccine trials, were established in response to the premature ending of the 
tenofovir trials in these two countries. 
 Several lessons were learned from this study: one of the major ones was that it is not 
sufficient for researchers to maintain high ethical and scientific standards in a study; in many cases, 
it is equally important and necessary for them to work very closely with the communities through 
various flexible mechanisms. Examples of such mechanisms include the community advisory 
boards (CABs), as well as the local ethical review boards (ERBs). In cases where community 
engagement is relevant, participation should commence from the very start of the protocol 
development. Participation should focus on the methodology, participant selection, the procedures 
for the study results disseminations at different points of the research and finally on enhancing 
informed participation. Any consultation with the community after the protocol is developed may 
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1.1 Background to the study 
 Globally, there are wide disparities in economic development in terms of the burden of 
diseases and health outcomes (Evans, 2001), and there is a high probability that, without the 
necessary precautions and human rights protections, the continuously accelerating trends 
towards globalisation will only make these health inequalities worse. Health can be regarded as 
wealth and thus the bedrock and foundation of development: “Good health is a cornerstone of 
economic progress … and indeed the primary objective of development” (Chen & Berlinguer, 
2001). 
In order to improve and develop health care in terms of health care delivery, services, 
programmes, treatments and techniques, research is very important. In the absence of research, 
we will not progress and we will have no empirically tested body of knowledge underpinning 
our service, practices or commissioning. In other words, in the absence of research, we would 
neither move forward nor would we be able to evaluate the efficiency and effectiveness of what 
we do now since only research can tell us that. 
Health research is well known to be the main route in establishing the causes of sickness 
and discovering new approaches in treating and alleviating pain or illnesses. It generates a 
wealth of data that leads to the enhancement of the quality of human life. Many diseases, known 
to have caused high mortality and morbidity rates in the world in the past (e.g. diarrhoea, 
measles, tuberculosis, HIV/AIDS, etc.), have now been contained through different preventive, 
diagnostic, treatment, and public health policies and methods which have been developed 
through health research. 
Because of research, many health professionals can now enjoy the excitement and 
challenge of a variety of research-related careers. However, it is important not to overlook the 
relevance and role of research participants in this research success. Contributions from research 
participants include offering their time voluntarily, often without any gains to themselves, and 
often under the most trying of personal circumstances; for these, and other reasons, appropriate 
respect for and protection of their interests are essential. 
While research is important for the improvement and development of effective health 
care services, it may also involve an element of risk since it often necessitates trying something 
new. It is imperative that any risks involved in the research be minimised and that the dignity, 
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rights, safety and well-being of those consenting to take part in the research are not 
compromised (Department of Health (UK), 2011). The respect for ethical research practices is 
central to attaining this objective. 
Violations of the rights of participants in health research aimed at advancing medical 
knowledge have occurred in the past, leading to the creation of guidelines to avoid re-
occurrence. The abominable acts carried out by the Nazi research physicians that were exposed 
at the Nuremberg trials after World War II, resulted in the creation of the Nuremberg Code for 
regulating experimentation on human subjects (Nuremberg Code, 1949). Similarly, the 
Tuskegee Syphilis study (1932-1972) led to the publication of the Belmont Report (1978) . 
Three principles that came out of this publication were ‘respect for persons’, ‘beneficence’ and 
‘justice’. These principles dominated research ethics for the latter part of the twentieth century. 
More recent developments in the governance of research have recognised the part that 
communities can and ought to play in emergent and inventive research studies. The Council for 
International Organizations of Medical Science (CIOMS), the Declaration of Helsinki, the UK 
Nuffield Council on Bioethics, the US National Bioethics Advisory Commission and the 
National Institute of Allergy and Infectious Diseases, as well as other research institutions such 
as the National Institutes of Health and the Centers for Disease Control and Prevention, have 
all recognised the importance of increased involvement from the community in the research 
process. In 2004, Emanuel and colleagues (Emanuel, Wendler, Killen, & Grady, 2004) 
recommended eight ethical principles with accompanying benchmarks for the conduct of 
research, among which was collaborative partnerships/community engagement. 
A key consideration in ethical research is in the recognition that research is done with 
people and not to them (Emanuel, Wendler, & Grady, 2000). When researchers collaborate with 
participants in research, it helps to guard against exploitation, as participants help design fair 
and just study practices. In addition, such collaboration helps in ensuring that the proposed 
research meets the community’s needs and expectations (Emanuel, 2011). 
The concept of community engagement (CE) originates from the works of Paulo Freire 
who argued for the encouragement of education of communities so that they might be 
empowered to act as agents of change (Freire, 1994). CE can lead to a population that is more 
informed, since engagement with the community will necessitate discussions and explanations 
of the research. These meetings for discussions serve as a great opportunity for potential 
participants to be informed and educated about the research. They also help to provide a 
platform to raise pertinent questions or concerns that participants might have about the research.  
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In medical research, CE came to the fore with the initiation of HIV research, and this 
was principally in the 1980s during the activism about access to HIV treatment. The relevance 
of CE was unambiguously noticeable during the tenofovir trials, which failed because of 
inadequate CE. These trials tested for the safety and efficacy of oral pre-exposure prophylaxis 
for the prevention of HIV transmission (Staunton & Moodley, 2016).  
CE has been practiced in a variety of health-related research studies such as in the 
Navrongo Community Health and Family Project (CHFP) in Kassena-Nankana, Ghana (Binka, 
Nazzar, & Phillips, 1995), the Majengo Observational Cohort Study (MOCS) studying 
disadvantaged female sex workers in Nairobi, Kenya (Bandewar, Kimani, & Lavery, 2010), an 
epidemiological investigation of some 7-12 year olds in South Korea, and an Autism Spectrum 
Disorder (ASD) detection programme for 18-36-month-old Zulu-speaking children in South 
Africa (Grinker et al., 2012). 
It is now widely agreed that CE is an ethical requirement for some research and that it 
is indispensable to the success of a health research project; as a result of this, CE as a theme has 
been welcomed by researchers, sponsors and pharmaceutical industries. Regrettably, CE as an 
ethical requirement has at times been considered by researchers as an ethical procedure to be 
respected and followed (thus as a hedge), instead of as an integrated element of the research 
process. Due to this, insufficient consideration has been given to how and when CE should be 
undertaken and on the need for meaningful and genuine CE throughout the research process. 
This has led to CE being regarded as ‘pulling wool over the eyes’, something to be ticked off a 
list with the intention of gaining an advantage, when, in reality, it is not being taken too 
seriously. 
This is of great concern, since researchers and sponsors invest huge sums of money in 
product development, training on clinical procedures, facility designing and building, etc., and 
hitherto continuously neglect the relevance of meaningful CE processes. CE can help avoid or 
reduce conflicts and problems that might lead to the premature ending of research. There is no 
gain to any stakeholder in research when a trial is halted or closed for reasons which are non-
scientifically related. As demonstrated by the tenofovir trials, the failure to engage with the 
community adequately can come at substantial scientific cost. 
 Several projects implementing CE continues to fail thus leaving one with the impression 
that, CE has not being very effective whereas it could be the absent of a meaningful and genuine 
CE at fault. The recently early closed down Ebola vaccine trial in Cameroon in 2016 (Quinn, 
2004b) was a quick reminder to the researcher about what happened in the Tenofovir trial in 
2005 which had some of the major stakeholders in health research engaged but still had the 
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study closed down. Despite engaging with different stakeholders like the Ministry of Public 
Health, the different Regional Public Health Delegations and the health practitioners in the 
different regions, the Ebola study still experience an early shutdown just like the Tenofovir 
study. So looking at this situation and several more, the researcher thought that the was need to 
rethink the current practices of CE in a way to avoid several other studies from shutting down 
probably as a result of  glitches that could otherwise occur as a result of the absent of meaningful 
and genuine CE. 
It is the researcher’s hope that meaningful CE rather than just ‘mechanical’ CE will be 
embraced by researchers as one possible avenue to increase trial successes. 
 
1.2 Structure of the dissertation 
 This dissertation is structured into six chapters. The first chapter is the introduction, 
which presents the historical evolution of the concept of health research ethics and community 
engagement. The second chapter presents the different literature reviews that were relevant to 
the subject matter. The third chapter deals with the methodology of the study. The fourth 
chapter presents the case studies. The fifth chapter discusses the findings, while the last chapter 
addresses the possible measures that could be used to resolve some of the concerns and 









2.1 What is research ethics? 
 Research ethics refers to the moral principles that inform and guide research practices. 
These have a specific focus on ethical issues that may be encountered when enrolling humans 
in a study as research participants. Several research ethics codes do exist, and most are largely 
concentrated on the following key principles: participant protection, conducting research of a 
high standard, planning and executing research with ethical honesty and trustworthiness, such 
as the informed consent process, protection of confidentiality and risk management, and 
guaranteeing transparency of the entire process of the research. 
When people think of the word ‘ethics’, they tend to think of a set of rules that 
distinguish between wrong and right. Example of such rules include the Golden Rule (“Do unto 
others as you would have them do unto you”) (Etzioni, 1996); codes of professional conduct 
like the Hippocratic Oath (“First of all, do no harm”) (Jonsen, 1978); the religious creeds like 
the Ten Commandments (“Thou shalt not kill.”); or a wise adage like the wise words of 
Confucius. 
For this thesis, ethics is understood as the science of principles, standards and tenets for 
human action and conduct that seek to address philosophical questions about morality. Ethics 
is involved in reflections and analyses of morals regarding whether an act is bad or good and 
how it influences our fundamental quest for meaning. It also involves our pursuit for the well-
being of humankind and our effort to construct a humane society, having as goal the 
safeguarding of human dignity and the promotion of truth, equality, trust and justice. In essence, 
ethics entails a critical reflection on morality (Benatar et al., 2007). 
 
2.2 Community engagement 
2.2.1 Why is community engagement important? 
The term ‘community’ can refer to a group of persons living in the same local geographical 
location or having some other non-spatial common social identity. This social identity may 
include a similar trade or group membership. For this study, the term ‘community’ will be 
understood as group of persons with a mutual social identity, as defined by Kathleen MacQueen 
(MacQueen, Bhan, Frohlich, Holzer, & Sugarman, 2015). The term ‘engagement’ will indicate 
some form of relationship between a community and the research body. 
6 
 
The idea of community engagement (CE) as an ethical requirement for research that 
involves human participants, mainly marginalised populations, has made its way into many 
(international) guidelines on research ethics. Several reasons account for this valuing of CE in 
health research, as can be found below. 
Firstly, CE can improve the impact, quality and significance of a research study (Cargo 
& Mercer, 2008; Israel, Schulz, Parker, & Becker, 1998a), and cooperation with community 
members and their representatives has given researchers, often from diverse cultures and socio-
economic backgrounds, new points of view and respect for a community’s values and interests 
from the perspective of the study participants. This has helped to improve study designs and 
methods and also increase study participant recruitment and retention. It has also increased 
consent and study enrolment, and led to the production of valid and more significant results 
(O'Fallon & Dearry, 2002). 
CE has been recognised as an essential activity that can be used for promoting the ethical 
conduct and successful implementation of research. This is done by ensuring that research 
conducted is locally relevant to the host community and that viewpoints of the local populations 
are integrated into the research design during the conduct of the study (Dickert & Sugarman, 
2005; Emanuel et al., 2004). 
CE is also important in that it helps to extend the ethical principle of ‘respect for 
persons’ to the entire community. This may avoid exploitation and build confidence between 
researchers and the communities taking part in the research (Lakes et al., 2014; Tindana et al., 
2011).  
CE permits members of the community to express their concerns, priorities or 
reservations about the research. It also permits researchers to identify vulnerable populations 
(groups of persons incapable of fully protecting their own interests). Engagement may also 
facilitate the identification of potential consequences of, or implications for, the research that 
might not have been anticipated by the researcher. Furthermore, CE permits the community, as 
a group, and the individual potential research participants, to think about the risks and benefits 
involved in participation and to assess the defined protections put in place for them. 
CE assists in creating beneficial, collaborative and transparent relationships between 
potential researchers and the communities with which they might work to conduct the research 
(UNAIDS/AVAC, 2007). This is very important since favourable relationships between 
researchers and communities can promote trust in scientific research, as well as lead to greater 
recognition of scientific results. These relationships could equally lead to the identification of 
potential future research endeavours that might be beneficial to the community. 
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Involving community members and representatives in conducting the research also 
helps to increase awareness and knowledge amongst the community. Participation can also help 
create trust between the communities and the researchers, and this will help to increase the 
probability that community members will be aware and take advantage of any benefits that may 
emerge from the research (2011) .   
CE helps to ensure that communities more prone to shouldering the burdens of research 
unequally have fair access to the benefits of the research, as the principle of justice requires. 
Engaging the community in the protocol planning, participant recruitment and research results 
dissemination can provide a great opportunity for communities to identify groups that might 
need specific consideration. Identifying these sets within the population may help prevent either 
overburdening such groups or forgetting them from the final dissemination of the research 
outcomes. 
More generally, Dickert and Sugarman (2005) have identified four main values of CE. 
These are protection enhancement, enhancement of benefits, creation of legitimacy and sharing 
responsibilities; these are facilitated by the integration of the opinions of the community and its 
participation in research (Dickert & Sugarman, 2005). 
At all levels, there is a blurred difference between “CE” and “stakeholder engagement”. 
Depending on the definition of community that is adopted, any interactions with research 
stakeholders, such as the media, policy makers, ethics committees, Ministries of Health, 
international organizations and universities, could be regarded as a form of CE. Linking the 
term ‘community’ to ‘engagement’ serves to shift the focus from the individual to the collective, 
with a focus on inclusion of diverse stakeholders within any community. The term stakeholder 
could be understood as individuals or organisations with a specific stake in the outcome of a 
decision to the impact of a policy, project or proposition sufficient to justify engagement but 
who may or may not have geographic proximity to potential research project sites (Kolopack 
& Lavery, 2017).  Hence stakeholders can be part of your community, or your community 
members can be stakeholders 
 
2.2.2 Challenges of community engagement 
 A key challenge emerging in discussions of CE relates to the understanding of the term 
“community” (Ernst & Fish, 2005a; Q. Karim et al., 2006). Defining and understanding what a 
community is, constitutes a great challenge since it is only through an adequate definition of 
what this entails can engagement begins. What constitute a community seems to be evolving in 
this time of globalisation and this poses a great challenge to researchers as their lack of 
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understanding of what a community is makes them to leave out certain important communities 
in the engagement processes which always come at considerable cost to them in the future.  
 The next challenge revolves around lack of funding from funders (Swainston & 
Summerbell, 2008). This is seen to be the biggest challenge as without such funding allocation, 
CE activities cannot be carried out by researchers. So the lack of CE or inadequate CE could 
be link to funders/sponsors and not entirely blamed to researchers as it has been seen most 
often. There is need for funders to understand the relevance for CE activities and make 
considerable funds available for its activities. 
 Another challenge with CE has been the power struggle between stakeholders 
(Swainston & Summerbell, 2008). This is a big challenge mostly in very big projects as the 
different stakeholders fight to position themselves; due to their societal influence and status; to 
imposed their decisions or override the decisions of other stakeholders. This is very costly to 
the overall success of the project as it gives room for personal interest and ego over collective 
interest and overall goal of the project. This constitute a big challenge for CE in research 
projects and calls for an urgent need to harmonise every stakeholders effort into archiving the 
common goal designed for the given project. 
 Lastly, another challenge that could be noticeable in CE is that associated with certain 
cultural practices and social settings as in some societies, it would be considered culturally 
inappropriate for researchers to ask individuals to participate in research without consulting the 
community or obtaining permission from community leaders. Thus it is important to understand 
these challenges and identify solutions to overcome them prior to the commence of the research 
study. 
 
2.2.3 Types of community engagement 
CE can be and is applied in several ways and to different extents, and the level of engagement 
covers a broad spectrum, depending on the kind and intricacy of the project(s) involved 
(Fleischman, 2007). These are discussed below. 
 
2.2.3.1 Traditional research: This type of research method marks the ‘lowest’ end of the CE 
spectrum. This is so because, historically, research has been driven mainly by prior 
experimental data and funding priorities. Protocol designs by researchers in traditional research 
do not seek inputs from participants or the community at large on the scientific methods, ethical 
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requirements, and feasibility of the study throughout the research process. Participant 
recruitment is classically centred on scientific criteria that are specific to the protocol, and 
researchers figure out the best ways to reach out to the members of the community for the 
purpose of recruitment. In this type of research, researchers are linked to the community only 
through the research project and nothing else. In this research method, researchers do all the 
work such as collecting, analysing, and interpreting data, reporting results, and publishing 
findings on their own while the members of the community typically have no role to play in the 
research, beyond being research participants. 
 
2.2.3.2 Community-engaged research: This type of research method extends through the 
biggest part of the CE spectrum, and the inputs of members of the community are sought in 
identifying relevant issues for the study, creation of culturally suitable study designs, or in 
identifying and incorporating ethical considerations into the design of the study and the 
strategies for the recruitment of participants. The establishment of community advisory boards 
(CABs) for consultation with researchers is a popular method that visibly indicates that 
researchers value the inputs of the community. However, this approach is limited in that 
community representatives are not considered as full partners in the research endeavour. 
Usually, every partner in the research process carries equal weight in every research-related 
process of making decisions; however, this is not the case for the CABs, as they are limited to 
providing information whilst having no power to make final decisions. Members of the 
community might be involved at times during the collection and analysis of data, and this 
analysis, interpretation, and dissemination of results is shared openly with the community. 
Along the community-engaged research spectrum, the degree of engagement and 
collaboration between researchers and members of the community could be depicted as 






Figure 1: Continuum of community engagement mechanisms.  
Source: Clinical and Translational Science Awards Consortium and Community Engagement 
Key Function Committee Task Force on the Principles of Community Engagement. (2011). 
Principles of community engagement (2nd ed.). Bethesda, MD: National Institutes of Health, 
p.8.  
 
2.2.3.3 Shared leadership model: This type of research method represents the maximum level 
of community participation in research. In this model, members of the community function as 
full partners in the research study. The communities assist in identifying the topics or issues for 
study based on their priorities. These communities actively participate in designing the study 
and providing guidance to the researchers concerning the recruitment and retention of 
participants. Community members are also involved in collecting data – data that is shared with 
the community and the researchers in collaboration with the members of the community, who 
normally work to analyse and interpret these data. 
Researchers do not only share the results with the community, but the community 
members themselves assist in disseminating the research results to the public. This research 
method stresses capacity building, for example, the involvement of the local community in the 
research process with the aim to strengthen skills, competencies, and at times infrastructure, so 
as to deal with prevailing social and/or economic hurdles within the community. This approach 
is the best and the approach that is recommended for every researcher/investigator to implement 





2.3 Theories upon which thesis will be based 
 CE has been linked to development practices which came into global health research in 
reaction to calls to see much greater research community representation and participation, 
especially from vulnerable persons (MacQueen et al., 2015). 
The establishment of different international ethical guidelines has facilitated the 
protection of research participants in research. These guidelines include: the Nuremberg Code 
established in 1947; the Declaration of Helsinki, with the first version in 1964 and the most 
recent in October 2013; the Belmont Report of 1979; the Council for International 
Organizations of Medical Sciences (CIOMS) ethical guidelines, with the first version in 1982 
and the most recent in 2016; the International Council for Harmonisation (ICH) Good Clinical 
Practice guideline issued in 1996; and the UNAIDS/AVAC Good Participatory Practice (GPP) 
guidelines, with the first version in 2007 and the most recent in 2011. Drawing from the 
different international guidelines, Emanuel et al. (2004) proposed eight ethical principles, with 
accompanying benchmarks, for the conduct of research; among these was collaborative 
partnerships/community engagement. 
Hashagen (2002) argues that the use of the word ‘engagement’ means that those in 
charge of community planning should think properly about the communities they intend to work 
with. This is to enable them to understand the community’s culture and history, an array of local 
needs and matters, and how they are perceived, the nature of local community networks and 
organisations, the strengths and assets of the community that they might capitalise on and, 
finally, the nature of prevailing dialogue and community participations. 
Aslin and Brown (2004) articulate that CE is not something to be done once and 
forgotten about but rather a continuing process, with the goal of “engaging the community to 
take action” (p. 3). Furthermore, these authors stress that the CE process does not stand alone 
but rather forms a part of another process known as “decision-making for a particular purpose” 
(p. 3). These two authors emphasise that engagement “... goes further than participation and 
involvement and it involves capturing people’s attention and focusing their efforts on the matter 
at hand … Engagement implies commitment to a process that has decisions and resulting 
actions meaning that it is possible to consult people, get them to participate, to be involved 
even, but not engaged” (Aslin & Brown, 2004, p. 5). Of utmost significance to this explanation 
are the commitments by the participants – both the researchers and the communities – for 
without commitments, there is not likely to be any sustained and meaningful engagement. 
Two schools of thought can be applied to the concept of CE (Brunton et al., 2017). They 
include the utilitarian and the social justice perspectives. These two perspectives often appear 
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in CE literature. Health researchers and authors take different positions regarding these two 
perspectives and, depending on their perspective, may approach CE quite differently. 
Researchers from a utilitarian perspective consider research to be good or bad for the 
community based on the consequences or outcome of the research to the community. In theory 
at least, this means that if a community benefits from research, even without being engaged 
with in the research process, the research is ‘good’. 
From the social justice perspective, less emphasis is placed on the instrumental usage 
of CE to attain a certain end (as with the utilitarian perspective), than to the development and 
empowerment of the community itself. The ladder of citizen participation by Arnstein (1969) 
is the oldest and probably best-known model centred on social justice. This method of 
participation ranges from non-participating methods of manipulations, via ‘tokenistic’ 
placation, informing and consultations, to ‘power-sharing strategies’ of partnership and power 
delegation. With the use of this model, CE procedures near the foot of this ladder of 
participation might comprise information dissemination about the planned research, while 
research mechanisms at the topmost part of the ladder can provide lawfully established 
representatives as veto powers in relation to the proposed research. This study will focus on the 
social justice perspective, which is founded on empowerment of the community members, 
which is required for genuine and meaningful engagement. 
According to MacQueen and colleagues (MacQueen, Eley, Frick, & Hamilton, 2018), 
the numerous gaps in and challenges with CE are a reflection of the outlier status of CE to 
(some) stakeholders. This means that CE is often regarded as an auxiliary to trials rather than 
as an integral element, with equivalence to the regulatory, laboratory, clinical, laboratory and 
statistical elements. This problem – where engagement is viewed myopically as an instrument 
or procedure for buttressing clinical trials – has profound repercussions. Pantelic and colleagues 
argued that engagement ought not to be regarded as a method but rather as an orientation that 
needs to be incorporated into the designed and tried intervention (Pantelic, Stegling, 
Shackleton, & Restoy, 2018). These authors made the case to shift the nature and focus of HIV-
prevention research towards the individual’s needs and interests. They proposed that obstacles 
to improving and incorporating knowledge about CE in research be addressed through 
community‐based participatory and person‐centred research techniques. 
Despite the fact that CE is relevant for the ethical conduct of research, it cannot be 
implemented in all kinds of research situations (Weijer & Emanuel, 2000). This is because there 
do exist differences in cultural and social norms, goals, values, resources and technological 
understandings between researchers and typical community participants; these must be taken 
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into consideration, if research is to be conducted successfully right to the end (Doumbo, 2005; 
Leach & Fairhead, 2011; Mitchell, Nakamanya, Kamali, & Whitworth, 2002; Molyneux, 
Wassenaar, Peshu, & Marsh, 2005). Weijer and Sharp’s analysis stating that prospective 
systems of engagement are based on particular community attributes offered a useful conceptual 
framework for this study (Sharp & Foster, 2000; Weijer & Emanuel, 2000; Weijer & Miller, 
2004). 
 Possibly the best-known mechanism for CE in international research has been the use 
of community advisory boards (CABs). CABs are defined as “being composed of committee 
members who share a common identity, history, symbols and language, and culture” (Strauss 
et al., 2001, p. 15). Marshall and Rotimi describe CABs as an example of an approach of 
“safeguarding the interests of local populations, through the establishment of a solid foundation 
that supports a relationship based on trust and engagement with community members” 
(Marshall & Rotimi, 2001, p. 243). A strong CAB is one which is established based on a 
stronger relationship with the researcher and is sustained over time, usually longer than the 
lifespan of any particular research study. 
 CABs are now generally accompanied by and balanced with other forms of engagement 
and participation so as to bring diverse community voices, viewpoints and worries to the fore. 
These forms of engagement include the use of traditional community assemblies (Vreeman et 
al., 2012), qualitative research as was for the case of Cameroon (MacQueen et al., 2007), and 
deliberative engagement processes (Lemke, Halverson, & Ross, 2012). One of the issues 
debated by CABs has been the quality of care to be offered to participants. Experiences in the 
field demonstrate that research participants cherish the high quality care they get at research 
sites (MacQueen et al., 2007; Ramjee et al., 2010). Offering high quality care is regarded as a 
means of ‘giving back’ to communities that have offered an accommodating environment for 
research in an effort to advance science. Participants find this experience extremely 
advantageous (Dawson, Klingman, & Marrazzo, 2014).  
The debate has raged over whether the level of care being offered should be equal to 
that available in the home country of the sponsor of the trial or be comparable to the best 
standards of care obtainable within the country where the trial is taking place, though not 
necessarily within the actual location of the trial (MacQueen et al., 2007). In terms of HIV 
research, many commentators are of the opinion that researchers have some positive 
responsibilities to assist those trial participants who seroconvert during the study (MacQueen, 
Karim, & Sugarman, 2003). Unfortunately, it has been recognised that even in the presence of 
state-of-the-art technologies for testing the intervention, ‘offshore’ trials cannot deliver the 
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same quality of care as is obtainable in the country of the trial sponsor (Craddock, 2004; 
Kalipeni, Craddock, Oppong, & Ghosh, 2004; MacQueen et al., 2007). 
 There has also been wide debate on the associated ethical challenges in HIV research 
regarding prevention and treatment, both at the national and international levels (Lurie & 
Wolfe, 1997; K. MacQueen, Shapiro, Karim, & Sugarman, 2004; Rennie, Muula, & Westreich, 
2007). One of the challenges centres on the much greater distance existing between the 
theoretical ideal and the reality of individual understanding in circumstances where participants 
might lack proper education. Not only do several languages not have words for fundamental 
terms such as ‘hypothesis’ or ‘research’, ‘false positives’, ‘placebo’ and ‘randomization’ 
(Ekunwe & Kessel, 1984; K. MacQueen et al., 2004; Molyneux, Peshu, & Marsh, 2004; 
Moodley, 2002), they may even lack corresponding concepts. Comprehension of the 
information discussed during the consenting process may well be improved by way of 
counselling and consultation with cultural authorities and/or local cultural representatives, 
(Fitzgerald, Marotte, Verdier, Johnson Jr, & Pape, 2002; K. MacQueen et al., 2004; Marshall 
& Rotimi, 2001; Strauss et al., 2001; Woodsong & Karim, 2005), hence the need for CABs. 
 A key challenge for CABs has been to identify stakeholders who have legitimate and 
genuine interests. By this is meant identifying stakeholders who will avoid politicisation and 
will reliably represent their communities (Dickert & Sugarman, 2005; Foster et al., 1999; 
Marshall & Rotimi, 2001; E. J. Mills et al., 2005; Sharp & Foster, 2000). Another challenge 
has been that there has been no instruction (either uniform or adapted to local contexts) 
regarding what indicators should be used in addressing ethical issues raised by the use of CABs 
or regarding how they might best be used to improve post-trial benefits and reduce potential 
community exploitation (MacQueen et al., 2015). Also another challenge of CABs resides on 
whether CAB members should be compensated financially for the work they do since most at 
time individuals available to participate in CAB’s activities may be unemployed and therefore 
have challenges meeting their daily needs(Manda-Taylor, 2013; Morin, Maiorana, Koester, 
Sheon, & Richards, 2003a). While it could be justify that there is a strong positive  relationship 
between compensating CAB members for their time and with their greater commitments to the 
CAB’s activities(Mott, Crawford, & Group, 2008), the problem associated with this approach 
comes when this compensation is being provided for by the research group.  If the research 
group provides for the compensation, then there is a possibility that the CAB members may be 
influenced in their decision making in favour of the research team (Israel, Schulz, Parker, & 
Becker, 1998b; Lo & Bayer, 2003; Quinn, 2004b). Lastly, both scientists and CAB members 
have raised the issue of insufficient power being given to community representatives and of 
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their actions being largely limited to advising and giving feedback to researchers (Lwin et al., 
2014; Manda-Taylor, 2013; Pratt et al., 2015).  
A power shift is needed in which CABs can assume a more intrinsic role. This would 
include, for instance, participating in setting the study agenda with researchers and evaluating 
the appropriateness and relative priority of future studies (MacQueen et al., 2015). This is in 
contrast to having a purely instrumental role, such as providing guidance in the wording of the 
informed consent form or helping with recruitment and enrolment (MacQueen et al., 2015). 
Thus it is important for CE strategies to be informed by local advisors and occasionally re-
evaluated for results (MacQueen et al., 2015). In the absence of this, a well-intended proposal 
to engage specific communities might encounter obstacles that are well beyond the scope of 
any particular clinical trial and consequently make a generally ‘good practice’ non-effective. 
 In addition to these challenges by CABs are debates on: how the term community ought 
to be defined (Ernst & Fish, 2005b; UNAIDS, 2006); debate on the harmonisation of 
compensations and ensuring the independence of members (Morin, Maiorana, Koester, Sheon, 
& Richards, 2003b); debate on the need for resources for the training and sustainability of 
CABs’ activities; and lastly debates on the resolution of disputes resulting from individual- and 
community-level decisions (Quinn, 2004a; Sharp & Foster, 2000). Given the relevance of 
principal researchers in dispute resolution through negotiations, the efficacy of CABs has been 
tied to the connection between the principal investigator and the community (Sharp & Foster, 
2000).  
Several reasons account for why things might go wrong with a CE process. These 
reasons include poor planning, lack of commitment, lack of resources or interest from one or 
more stakeholders, bad timing, and so on. Dare and colleagues (Dare, Schirmer, & Vanclay, 
2008) advised that it is important not to abandon a process or ignore any problem but rather to 
identify the causes of these problems in the process and (attempt to) fix them. 
It light of the above, the researcher tried to identify what exactly went wrong with the 
CE process during the tenofovir trials in both Cameroon and Cambodia. In looking at these 
trials, the study aimed to propose a way forward for other researchers who will be implementing 







2.4 History and development of tenofovir 
 The life cycle of the HI virus provides numerous specific goals for ARVs, and there are 
many classes of ARV microbicides that are now under development. Two of these are entry 
inhibitors and reverse transcriptase inhibitors (Garg, Nuttall, & Romano, 2009). Entry inhibitors 
can operate in different ways, with some impeding the binding of the HI virus to CD4 receptors 
and CCR5/CXCR4 co-receptors, hence hindering entry into target cells (Shattock & Moore, 
2003), while others interact with the gp120 on the HI virus. For this thesis, attention will be on 
the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), which irreversibly and 
allosterically combine to reverse transcriptase and thus prevent HIV duplications (Q. A. Karim 
et al., 2010). Reverse transcriptase (RT) is a viral enzyme used for the conversion of viral 
mRNA into double-stranded viral DNA. This can then be integrated into the host cell 
chromosome, thus permitting host duplication of the virus (Sarafianos et al., 2009). 
Consequently, RT is essential for HIV duplication and spread (Sarafianos et al., 2009), and 
inhibiting RT can potentially prevent infection. 
In practice, NRTIs have proven to be highly efficient in blocking the action of RT. 
NRTIs were the first class of antivirals approved by the FDA for HIV treatment (Young, 1988). 
All NRTIs are activated to triphosphate analogues by cellular kinases (Furman et al., 1986; Hart 
et al., 1992; Mitsuya, Matsushita, Yarchoan, & Broder, 1984; Mitsuya et al., 1985). NRTIs 
represent the pillar of highly active antiretroviral therapy (HAART) for the clinical management 
of HIV infection, hence this ARV class is important to the development of microbicides. This 
class is relevant because it can sustain ample anti-HIV activity all through the interval between 
when it is applied to the vagina or rectum and when the semen is the deposited (Karim et al., 
2010; Shattock & Moore, 2003). Amongst this ARV class is tenofovir (TFV), which is an 
acyclic nucleotide which speedily changes over within cells from TFV monophosphate to its 
active form TFV-diphosphate (TFV-DP) (Birkus et al., 2007; Herman & Sluis-Cremer, 2012; 
Q. A. Karim, 2013). 
ARV drugs are proven to be efficient in the control of HIV for persons already infected. 
The biggest question surrounding ARVs has been to find out if it is possible for antiviral 
treatment to reduce the risk of the transmission of HIV, if it is taken as a form of prophylaxis 
prior to exposure to the virus; this marks the beginning of the tenofovir story. As discussed 
above, tenofovir is a long-acting ARV drug of the RT inhibitor class; it can be consumed once 
daily and has fewer side effects than several older agents. In ground-breaking research, it was 
ascertained by scientists that TFV administered immediately after a monkey’s exposure to SIV, 
a simian virus like the HIV, could prevent infections to the monkeys (Black, 1997; Tsai et al., 
17 
 
1998). This result buttressed the notion that TFV could be used as a post-exposure prophylaxis 
for humans, and maybe as a pre-exposure prophylaxis in high-risk HIV-negative populations 
for infection prevention. 
The foundation for preventing sexual HIV acquisition with pre-exposure use of ARV 
drugs originates from the demonstration that ARVs prevent HIV transmission from an infected 
mother to her infant and from a study on animals. ARVs are the foundation for the prevention 
of mother-to-child HIV transmission, which was first demonstrated with peripartum zidovudine 
(Connor et al., 1994). More recent studies have equally proven that post-natal ARVs, which are 
offered to infants with continuing exposure to HIV via breastmilk, can considerably assist in 
HIV-risk reduction (Chasela et al., 2010). Therefore, these infant studies provided proof-of-
concept that ARV prophylaxis could be extremely effective in the context of HIV exposures 
that were known and ongoing (Mofenson, 2010). 
This form of chemoprophylaxis, pre-exposure prophylaxis (PrEP), is an approach for 
the prevention of HIV, in which an individual who is not infected with HIV is administered an 
oral or topical formulation of an anti-HIV drug to protect themselves against HIV infection 
(Van Rompay, Johansson, & Karlsson, 1999). It refers to the taking of daily medications by 
persons at very high risk of HIV infection, so as to reduce their risks of infection (Centers for 
Disease Control and Prevention, 2019). 
Currently, the only FDA-approved formulation of PrEP is Truvada, an oral co-
formulation of the nucleoside/nucleotide RT inhibitors TFV and emtricitabine (Barry et al., 
2014; Meesters et al., 2011). Approval was issued in October 2004 for HIV treatment in adults, 
based on its efficacy and safety data (Louie et al., 2003; Schooley et al., 2002; Squires et al., 
2003; Staszewski et al., 1996). PrEP is believed to be a very promising approach to prevention. 
TFV is approved for usage as part of combination ARV therapy in the treatment of HIV 
infection for children two years and older, adolescents, and adults. Its high effectiveness and 
opposition to resistance, and its once-daily and single pill administration, has led to TFV being 
one of the favourite drugs for individuals with HIV infection (Aurpibul & Puthanakit, 2015; 
Lyseng-Williamson, Reynolds, & Plosker, 2005).  
 
2.5 An overview of a clinical trial 
 Clinical research is an important element of health care systems and contributes to the 
development of new therapeutic agents and interventions, and it improves existing clinical 
practices; at times, it  exposes the inadequacies of health care systems (Friedman, Furberg, 
DeMets, Reboussin, & Granger, 2010). Clinical research is carried out using different methods; 
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nevertheless, clinical trials are currently the leading method of clinical research (Friedman et 
al., 2010; Piantadosi, 2005). 
The term ‘clinical trial’ was first used in the early 20th century by the British Medical 
Research Council (International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH), June 10, 1996; Lefebvre, Eisinga, McDonald, & Paul, 
2008). The term ‘trial’ comes from the Anglo-French ‘trier’, which means to try. The term 
‘clinical’ comes from ‘clinic’, from the French word ‘clinique’ and the Greek word ‘klinike’ – 
both referring to the practice of caring for the sick at the bedside. Thus a clinical trial could 
narrowly be regarded as the action or process of putting something to a test or proof at the 
bedside of the sick. Broadly, it could refer to any testing done on human beings with the aim of 
determining the value of a treatment for the sick or for preventing disease or sicknesses. 
A well-designed clinical trial involves a particular kind of method that permits 
researchers to test an intervention, idea or drug. The advent of ‘clinical trials’ as a process for 
testing the efficiency of drugs developed accidentally. Surgeon Ambroise Paré is known to have 
carried out the first documented clinical trial of a novel therapy in the 1500s. He did this when 
he treated wounded soldiers with an alternative to the standard-of-care treatment, due to the low 
supply of the standard treatment and, in great surprise, this alternative treatment appeared to be 
more effective than the standard treatment (Bhatt, 2010) 
Some scientific research studies which compared treatments were carried out in the 18th 
and 19th centuries, and these included studies on smallpox and cholera. The most prominent 
intervention trial carried out was that by James Lind. Lind was a surgeon, and the trial was 
conducted in 1747, involving twelve sailors who had scurvy (Lilienfeld, 1982). Lind divided 
them into six groups of two and assigned each group a different existing treatment (Bhatt, 
2010). According to (Chalmers, 2003): 
In Lind’s opinion, one reason for the prevailing confusion about the diagnosis, 
prevention and cure of scurvy was that ‘no physician conversant with this disease at sea 
had undertaken to throw light upon the subject’. He set about filling this gap, with a 
clear commitment to base his work on  “‘Observable facts’ rather than the theories of 
medical decision-making at that time”(p. 1). 
 
This comparison by Lind became the first documented ‘prospective controlled trial’.  
The UK Medical Research Council (MRC) planned and executed the first known 
double-blind controlled clinical trial of the patulin drug in 1946; this was designed in response 
to public pressure. The public wanted to know whether patulin, a product purportedly 
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discovered by a group in the Royal Navy and anticipated to be better than penicillin in the fight 
against the common cold, was in fact, more effective. The members of the trial committee 
chosen by the MRC comprised biostatisticians and physicians, making this a ‘rigorously 
controlled trial’ (D'Arcy Hart, 1999). The first true randomised clinical trial was carried out by 
the British Medical Council in 1948. This trial involved 100 patients and studied the effects of 
streptomycin on tuberculosis treatment (Medical Research Council, 1948). 
The broad definition of ‘clinical trial’ comprises explanations that allow for the use of 
the term in reference to studies which involve a single treatment (for example, most phase I 
trials and some phase II drug trials) and for trials that involve the use of an external control (for 
example, studies that involve historical controls) (Meinert, 2012). In this research, the term will 
be used for referring to trials that involve two or more treatment groups consisting of persons 
who are enrolled, treated and followed up over a specific period of time. 
Research with human participants is currently regulated in several ways and at different 
levels. Clinical trials are guided and implemented according to a clinical trial protocol, which 
contains information on scientific evidence supporting the trial and on how the trial will be 
carried out, including its design, eligibility criteria of the participants and the outcomes to be 
measured. Protocols of clinical trial are sent to regulatory bodies such as clinical trials registries 
and ethics committees for review and approval (Kerr, Knox, Robertson, Stewart, & Watson, 
2008).  
Funders and sponsors of clinical trials research range from pharmaceutical companies, 
national research bodies, charitable foundations to private donations. Trials are carried out in 
private clinical laboratories, universities, medical centres, hospitals and research facilities, with 
persons from different fields taking part in the design, conduct and management of the studies. 
The research team is made up of, but not limited to, nurses, medical practitioners, scientists and 
other health care professionals, ethics committee members, the sponsor organisation, 
statisticians, epidemiologists, and carers and patients (Kerr et al., 2008). Clinical trials are 
carried out in a broad range of clinical and disease contexts, and differ in their aims, objectives, 
purposes and designs. That said, five broad categories that relate principally to the objective of 
the clinical studies, are commonly used for categorising clinical trials. These classifications are 






Table 1: Categories of clinical trials research (Sateesh, 2008) 
Treatment trials New drug combinations, new methods of radiation therapy or 
surgery, test experimental treatments 
Prevention trials  Evaluate approaches for the prevention of diseases in persons who 
have never had the disease or the prevention of a disease from 
coming back; such methods may include vaccines, minerals, 
medicines, vitamins, medicines or lifestyle changes. 
Diagnostic trials Carried out to discover better processes or investigations for 
diagnosing specific conditions or diseases. 
Screening trials Testing the best ways for detecting certain health conditions or 
diseases. 
Supportive care 
trials or quality of 
life trials 
Exploring ways of improving the quality of life and comfort for 
persons with chronic illnesses. 
 
Generally, clinical trials are carried out in four phases, with each phase having a different 
purpose designed to help the investigators to answer different questions (see Table 2). Phase I 
clinical trials are often comprised of tests with small groups (20-80) of human participants. 
Tests here are geared at determining the safety of the drug in terms of most common side effects 
and metabolism in humans and, at this phase, enrolled participants are mostly healthy 
volunteers. Research results here are deemed successful if the level of toxicity is judged 
acceptable.  
Between phase I and II trials proof-of-principle studies are at times carried out on 
humans so as to get supplementary indications of efficacies prior to going to phase II. A phase 
II clinical trial may begin after suitable IRB/REC approval. Phase II clinical trials are conducted 
on larger groups (amounting to some 300 participants) and are aimed at evaluating the efficacy 
of the drug in humans. Phase II clinical trials usually involve comparing the investigational 
drug to either a placebo (a substance that is inactive) or another drug. Phase III trials may only 
commence if the phase II trials ended on a positive note in terms of the drug’s effectiveness, 
and here the objective is to assess further the safety and efficacy of the drug in 300 to 3,000 or 
more participants. Participants here are principally persons with conditions related to the drug 
being tested, and such trials are always carried out in multiple sites and are accomplished by: 
testing the drug in diverse populations; testing varying doses of the drug; and probably using it 
in combination with other drugs.  
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After successfully completing phase III clinical trials, the pharmaceutical company may 
submit a New Drug Application (NDA) which, if approved, would result in permission being 
granted to bring the new drug onto the market. The process of NDA review entails reviewing 
both animal and human testing data by an expert team. This team of experts reviews the 
proposed information to be put on the drug labels and inspects the facilities for the drug’s 
manufacture. The phase IV clinical trials are carried out after a drug has been approved for 
marketing and aims to find supplementary data “about a drug’s safety, efficacy or optimal use” 
(Lada, 2016, p. 30).  
 
Table 2: Clinical trial development phases I-IV (Sateesh, 2008) 
Phase Description Example of study 
population 
Phase I Researchers testing an investigational treatment or drug 
within a small group of persons for the very first time. 
Test here is geared at evaluating the drug’s safety, 
determining a safe dosage range, and identifying side 
effects of the drug. 
20-80 persons, usually 
healthy volunteers or 
persons with disease of 
interest 
Phase II The investigational study treatment or drug is 
administered to a larger group of persons with the disease 
of interest. The aim here is to find out if the drug is 
effective, and to further assess its safety. 
100-300 people 
Phase III The investigational study treatment or drug is 
administered to large groups of persons to confirm its 
effectiveness and to monitor its side effects. In addition, it 
is given to compare the study drug or treatment to 
generally used treatments or placebo in a randomised 
controlled study design. It also collects information that 
will permit the investigational treatment or drug to be 
used safely. 
301-3,000 or more people 
Phase IV Post-marketing studies geared at gathering supplementary 
information such as the drug’s benefits, risks and best use. 
General population 
 
In spite of the above-mentioned range of clinical contexts, objectives and trial types, there are 
shared characteristics of clinical trials that differentiate this research methodology from other 
approaches. First of all, a clinical trial is a potential study design where participants are 
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monitored in time from a clear distinctive instant, where they are identified, selected and tested 
from the initiation point (Friedman et al., 2010). Also, clinical trials are carried out in settings 
which allow for the control of main variables like the measurement and intervention initiation 
of confounders and covariates, which helps in minimising bias (Piantadosi, 2005). 
 Clinical trials are the backbone of modern-day medicines and, since the Lind scurvy 
trial, clinical trials have evolved into a standardised procedure with focuses on scientific 
assessment of efficacy and patient safety guardians. As the field of the development of drugs 
continues to be improved by innovative technologies and therapies, there will always be an 
ongoing exigency to balance patient safety and medical progress. As scientific developments 
continue, so will there be new ethical and regulatory challenges. These challenges will require 
dynamic updating in the legal and ethical frame of reference of clinical trials in order for them 




























Research has been defined as a systematic method of collecting and logically analysing 
data for a particular objective (McMillan & Schumacher, 2010). Research methods have been 
established in order to acquire knowledge reliably and validly. A research method is focused 
and systematic, aimed at yielding data for a specific research problem (McMillan & 
Schumacher, 2010). This chapter will introduce and explain the rationale for the research 
methodologies chosen for the study. It begins by stating the aim of the research, providing the 
research questions and describing the research design. The chapter also includes a discussion 
about the reason for the choice of the case studies, the method of data collection, ethical 
considerations and the issues of validity and reliability as they relate to the research.  
 
3.1 Study aims 
The aim of this study was to demonstrate how inadequate CE might come at considerable 
scientific cost, whereas early, sustained and meaningful CE could contribute greatly to research. 
The researcher used the case of the tenofovir trials that were prematurely ended in both 
Cambodia and Cameroon in 2005 to draw lessons for future researchers. 
 
3.2 Main objective 
The main objective of this study was to understand the root causes of the early stopping of the 
tenofovir trials in both Cameroon and Cambodia in 2005, and with reference to the different 
international guidelines, to propose solutions for researchers embarking on similar research in 
the future. 
 
3.3 Research questions 
To address this research objective, the following research questions were posed: 
 How did the researchers understand the term ‘community’ during the tenofovir trials? 
 How were communities engaged during the tenofovir trials in Cameroon and 
Cambodia? 
 What lessons can be learnt from the tenofovir trials with respect to community 





3.4 Research design 
 Heppner, Kivlinghan and Wampold (1992) describe a research design as a structure or 
plan for an experiment or a list of requirements and procedures used for the conduct and control 
of a study. Simply put, a research design is a master plan indicating the strategies for carrying 
out the study. 
Who, what, where, how and why are typical research questions (Yin, 2003). The form 
a research question takes can suggest the most suitable investigation strategy. The ‘how’ and 
‘why’ questions can best be answered by case studies since this method allows for careful 
observation of the problem in question (Kothari, 2004). The study approach is termed a 
qualitative inquiry strategy, and it offers a learning method about a complex situation by way 
of a broad description and circumstantial analysis (Yin, 2003).  
Mitchell (1983) defines a case study as a “detailed examination of an event (or sequence 
of connected events) which the researcher thinks reveals (or reveal) the procedure of some 
recognised general theoretical principles” (p. 192). According to Gomm and colleagues 
(Gomm, Hammersley, & Foster, 2000), detailed research of peculiar occurrences in case studies 
can truly portray causative processes in context, which permits the analyst to appreciate which 
theoretical point of view offers the best explanations. According to another author (Stoecker, 
1991), a case study is able “to explain idiosyncrasies, which make up the ‘unexplained 
variance’” (p. 94). 
Qualitative research designs can be classified by: (a) focusing on personal lived 
experiences, such as in case study grounded theory, phenomenology and some critical studies; 
and (b) focusing on society and culture, as established by ethnography and some critical studies 
(McMillan & Schumacher, 2010). The researcher chose to use the qualitative research design 
type (a), which involves a case study approach, for the purpose of this study. This decision was 
triggered by the desire of the researcher to appreciate the relevance of meaningful community 
engagement in health research in the 21st century and, for that to be done, it required an in-
depth examination of the two case studies (Cameroon and Cambodia). 
  
3.5 Selection of the study materials 
The specific method used in collecting data/information for this research was collective 
review. Cooper (1998) suggests that a literature review provides the potential to propose much-
needed research in specific areas. Furthermore, he points out that theses with a focus on 
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literature review produce a wealth of data, which can then serve as the academic core for studies 
to be carried out in the future by identifying gaps and weaknesses in published knowledge. 
For this study, the stages of review advanced by Petticrew and Roberts (2006) were used 
for collective reviewing. Petticrew and Roberts (2006) summarised the stages of carrying out 
the review as such: the first stage is defining the study type (i.e., the literature review); the 
second stage is delineating the process for selection of literature to be included in the review, 
thereby applying the search strategy (Higgins & Green, 2008). For this research, electronic 
databases available to students of the University of KwaZulu-Natal, Google Scholar, and 
personal contacts and experts in the field for relevant authors were used to source literature. 
During the third stage, the researcher screened the material based on a structured classification 
system in order to structure and refine the literature review. Once the process of gathering and 
describing the research was completed, the researcher began the fourth stage of the review, 
which was assessing and synthesising the data. This involved appraising the quality and 
relevance of the data; synthesising the results of the studies; drawing conclusions; developing 
recommendations; and writing the final report (Major & Savin-Baden, 2010). 
Through this review, the researcher established the strength of assertions made in the 
literature. Firstly, the researcher reflected on the credibility, feasibility, coherence, 
intelligibility, and effect of the claims. Secondly, the primary literature researched was 
reviewed against its evidence. The researcher, in view of this, also considered aspects of 
reliability, reproducibility as well as significance. Thirdly, the researcher focused on data 
relating to the information concern. Subsequently, the merits of information were extremely 
important. 
Nevertheless, it should be noted that, only literature that could be verified by formal 
avenues was included in the review itself. The restricted focus implied by limiting the literature 
review to published literature did not indicate an absence of the researcher’s personal 
imagination, as implied by Cooper, as that could be vigorously noticed during the stages where 
sense-making (Abolafia, 2010) was applied to the data, and explicitly when correlated 
conceptions were analysed in the literature. What hopefully becomes apparent during the 
review analysis is that the collective results of reviewed literature are usually more combined 
in nature (analysis is on combined results from the different case studies and not just one) than 
taken into consideration in a separate study (as done on a case-by-case basis), and import is 
thus more powerful. 
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Higgins and Green (2008) point out that, while this methodology might seem slightly 
simplistic, this process is rigorous and laborious since the researcher systematically employs a 
range of theoretical and scientific opinions to establish the significance of the data. 
 
3.6 Selection of cases 
In order to conduct this research, it was necessary to identify clinical research studies 
that failed because of poor CE. Thus, in the selection phase, clinical studies that had failed 
because of reasons other than poor CE were excluded. Inclusion criteria consisted of the 
following: the study had to be a clinical trial, secondly, this clinical trial had to have been 
stopped prematurely, and lastly, the reason for the premature end had to be as a result of poor 
CE. Through this search, the Cameroon and Cambodia studies were identified as best fit for the 
study. Cameroon and Cambodia were chosen for convenience, availability of information, 
similarity and uniqueness in the cause-effect relationship (Blanche, Blanche, Durrheim, & 
Painter, 2006). In addition, a factor that contributed to the selection was that the major reason 
for the establishment of the Good Participatory Practice (UNAIDS/AVAC, 2007) guidelines, 
which set standard practices for stakeholder engagement in HIV vaccine trials, was the failure 
of these two trials. 
 
3.7 Data collection and procedure 
 Secondary data was obtained from the internet and the UKZN library. Different articles 
published online, text books, journals, reports, newspapers, and research dissertations were 
searched for on Google.com, Google Scholar.com and from the UKZN campus and online 
library. On the UKZN online library, platforms such as the EBSCOhost and SABINET were 
used for the search of current articles. Key words searched for included community 
engagement, tenofovir trials, clinical trials, health research, and Emanuel et al. eight 
benchmarks. The references cited in the different books and articles already published also 
served as a means for locating other articles for review.  
 
3.8 Ethical considerations 
 This study involved no human participants as research was done reviewing secondary 
(existing) data. However, this study obtained an Exemption from Ethics Review (BREC Ref 
No: EXM538/18) from the Biomedical Research Ethics Committee (BREC) of the University 




3.9 Reliability and validity 
 Reliability is a problem in the social sciences since human behaviours are under no 
circumstances fixed; this concept is founded on the hypothesis that there is a single reality and 
that repeatedly studying it will generate similar outcomes. This is in contrast with qualitative 
case study research, since researchers here strive to describe and explain the world as it was 
experienced by those in the world (Merriam, 2009). As there are several understandings of what 
is occurring, there is no standard means by which to determine reliability in the traditional 
sense; thus, the more essential problem for qualitative research is whether the results are 
consistent with the data collected. Consequently, the terms ‘consistency’ or ‘dependability’ are 
used. 
In this study, the researcher used the review of existing documents as the primary means 
of data collection. The reliability of the research results can be evaluated by the number of 
documents that were reviewed in order to establish the facts of the cases presented. The 
reliability of results can also be weighed through triangulation. This is the use of more than one 
method to research a problem. Triangulation aims to increase faith in the results through the 
validation of a proposal with the use of two or more independent procedures (Heale & Forbes, 
2013). Combining results from two or more painstaking methods offers a more complete image 
of the results than when only a single method is used (Teddlie & Tashakkori, 2003). 
External validity is the question of whether the empirical findings could be generalised 
(Calder, Phillips, & Tybout, 1982). As ascertained, the aim of case study research is to create 
profound understandings of the phenomena under investigation; this means it does not have as 
its aim the generalisation of the findings to other circumstances (Hammersley, Foster, & Gomm, 
2000). Thus, for this study, the external validity will be low. However, it is vital that a study is 
internally valid (Calder, Philips, & Tybout, 1983). Internal validity is concerned with the degree 
to which research results correctly reflect the phenomenon under study (A. C. Burns & Bush, 
2003), and to which they can be applied to other situations (Merriam, 2009). Simply put, 









4.1 Presentation of the tenofovir trials in both Cambodia and Cameroon 
 Information for the two case studies reported on this chapter is largely summarised from 
two case reports published under the auspices of The Global Campaign for Microbicides titled 
“Preventing Prevention Trial Failures: A Case Study and Lessons for Future Trials from the 
2004 Tenofovir Trial in Cambodia” and “Research Rashomon: Lessons from the Cameroon 
Pre-exposure Prophylaxis Trial Site”. Some additional sources were obtained from 9 peered 
reviewed articles (Cáceres et al., 2015; Folayan, Peterson, & Kombe, 2015; Mack, Robinson, 
MacQueen, Moffett, & Johnson, 2010; E. Mills et al., 2005; E. J. Mills et al., 2005; Nyika et 
al., 2010; Singh & Mills, 2005; Slevin, Ukpong, & Heise, 2008; Tangwa & Munung, 2011), 1 
PhD thesis (Bridget Gabrielle Haire, 2013) and a book (Brizi, Filibeck, Kangaspunta, & O'Neil, 
2009). 
 Methods for the prevention of HIV infection have been amongst the most pressing needs 
of global public health (A. UNAIDS, 2004), and one innovative technique used in clinical trials 
is pre-exposure prophylaxis with the ARV drug tenofovir, which is a proven drug used for the 
treatment of AIDS. The tenofovir drug was produced by Gilead Sciences in the United States. 
Gilead conducted trials to establish whether tenofovir could work as a prophylactic with the 
main purpose of testing the safety and efficacy profile of tenofovir for humans. The test 
procedure entailed the administration of a daily oral dose of either placebo or tenofovir to sex 
workers who had tested HIV negative at screening and then comparing the number of sex 
workers who took the oral tenofovir and seroconverted in the course of the trial to the number 
who seroconverted in the control group getting the placebo.  
Trials were stopped in Cambodia and Cameroon partly because of inadequate CE that 
led to misunderstanding and miscommunication. Other reasons for the early stopping of the 
trial included: unethical study design, study protocol concerns, inadequate access to care for 
participants who seroconverted, inadequate prevention counselling, and the lack of medical 
insurance for trial-related injuries, among others. Most of the controversies in the trials arose 
from failures to obtain appropriate consent, failures to engage with local research actors, and 






 The Kingdom of Cambodia, also known as the Khmer Empire, obtained independence 
from France in 1953. It is located in the southern portion of the Indochina Peninsula and is 
bordered by Thailand in the west/northwest, Gulf of Thailand in the west, Vietnam in the east 
and southeast, and Laos in the north and northeast. About 75% of central Cambodia is covered 
by a level basin that is bordered by the Mekong River and the Tonle Sap Lake. To the southwest 
of the basin, the Cardamom and Dangrek Ranges are located, with the last being a famous and 
well known slope that runs through the Thai border to the north. The coastline has a small plain 
faced by several offshore islands. Cambodia has a population of more than 15.8 million people 
(Japan, 2016). The main ethnic majority are the Khmer, who account for about 94% of the 
population, 3% are Chinese and 2.3% are Cham-Malays, while the rest are a mixture of small 
ethnic minorities such as Lao, Kola, Thai and Vietnamese. Cambodia’s official language is 
Khmer and the entire native population speaks it, even though the population equally speak 
some French and Chinese 
In November 27, 2001, the Bill and Melinda Gates Foundation held consultations on 
the proposal for a test of oral tenofovir in phase III trials in four countries including Cambodia, 
presented by Family Health International (FHI). In January 2003, the University of California, 
San Francisco (UCSF), provided a one-week training programme in Phnom Penh on “Ethical 
issues in research: Human subjects”. The Ministry of Health stakeholders, members of the 
Ethical Review Board of Cambodia, some sex workers and non-governmental groups attended 
this training. On February 28, 2003, the UCSF’s Committee on Human Research Institutional 
Review Board gave a one-year approval of the protocol. On 1 July 2003, the Cambodian Ethical 
Review Board gave a one-year approval of the preliminary protocol. On July 23, 2003, trial 
staff held their first community information session about the trial. On the March 4, 2004, they 
held their second Cambodia Community Advisory Forum.  
Starting in July 2004, growing pressure from activist-affiliated non-governmental 
organisations and activist groups influenced the Prime Minister of Cambodia, Hun Sen, to end 
the clinical trial preparations on August 13, 2004 (Forbes & Mudaliar, 2009). The Prime 
Minister said that “Cambodian people are not waste, and Cambodia is not a waste bin”, and that 
researchers should to take their trial somewhere else (Bridget G Haire, 2011). The spectacular 
protest against the Cambodian trial at the XV International AIDS Conference in Bangkok, 
Thailand, caught the attention of the world’s media (Chase & Naik, 2004).  
The Women’s Network for Unity (WNU), the union of Cambodian sex workers, led 
these protests. The WNU, which was launched in June 2000 by a group of sex workers, is a 
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union of Cambodian sex workers, which functions as an autonomously registered non-
governmental organisation (NGO). The WNU “provides a foundation for support and builds 
solidarity and self-empowerment among sex workers. The network provides a space for women 
to come together, share ideas and discuss the collective challenges they face” (Forbes & 
Mudaliar, 2009) . The network consist of more than five thousand general members from the 
sex worker population in Cambodia (Forbes & Mudaliar, 2009). In July, some WNU members 
attended the 2004 International AIDS Conference held in Bangkok and, for the first time, they 
were introduced to ACT-UP Paris (an international AIDS activist group that is stationed in 
many countries). On 14 July, during a Gilead-sponsored satellite session on antiretroviral, ACT-
UP (AIDS Coalition to Unleash Power) Paris and members from different sex worker advocacy 
organisations supported the WNU to put up an extremely visible protest against Gilead Sciences 
(the manufacturer of tenofovir). This massive protest brought tenofovir to the front of the 
public’s attention, with some key reasons for the protest cited as the following:  
 Purported insufficient prevention counselling offered to participants by the 
investigators of the study. This insufficient prevention counselling was regarded by 
the activists as a move by the researchers to allow research participants to become HIV 
positive during the trial since it was impossible for researchers to assess the impact of 
the test intervention without having a given number of participants becoming HIV 
positive during the trial. 
 The partial participation of the targeted communities in the design of the trial 
protocol. A preliminary protocol was submitted to the Ethical Review Board of 
Cambodia in March 2003; this was subsequently approved. It was only after the 
approval was obtained that the local population and different stakeholders were 
involved to help in the design of the different parts of the study (beside the protocol), 
such as the participant recruitment strategy. With this approval, the team was able to 
start formative research for the trial. They started employing staff and building the 
trial’s clinic and laboratory capacity. They equally began deliberating on the protocol 
in focus groups and interviews with stakeholders, made up of potential participants, 
local government officials, police and brothel owners.  
Dr. Margery Lazarus (a medical anthropologist at the University of California’s 
San Francisco campus) started the social research phase of the trial by carrying out 
detailed assessment of the risk behaviours, working conditions, demographics, and 
sexual and economic networks of the female sex workers in Phnom Penh. She also 
assembled a team of bilingual Cambodian staff, with selection criteria principally 
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based on their communication and qualitative research skills. Through her work with 
them, she assessed promising locations for the clinic site, designed and assessed the 
lucidity of informed consent materials and established a recruitment strategy for 
potential participants. Conclusively, the local population and different stakeholders 
were not involved in the design and conception of the study protocol, but were 
involved only after the study approval on aspects such as the design and development 
of participant recruitment strategy (Ahmad, 2004; Cohen, 2004; Forbes & Mudaliar, 
2009; James, 2004). 
 The limited community involvement in designing the study. The University of 
California, San Francisco, and the University of New South Wales, in order to carry 
out this trial, sub-contracted the Cambodian National Centre for HIV/AIDS, 
Dermatology and STDs (NCHADS), and Dr. Ly Penh Sun of NCHADS served as co-
principal investigator for the trial. Several foreign and local staff at NCHADS played 
key roles in the design of the trial. Dr. Ly Penh Sun and Dr. Vonthanak Saphonn led 
the NCHADS trial team. Dr. Mean Chi Vun, who served as the director of NCHADS, 
was very instrumental to the development of the trial. Conclusively, only staff at 
NCHADS participated in the design of the study protocol, while the rest of the 
participant community and different stakeholders such as the activists were never 
involved (Forbes & Mudaliar, 2009). 
 The non-provision of medical services and insurance to those who seroconverted in 
the course of the study or who suffered adverse events that were connected to the 
trial drug (Ahmad, 2004). Research participants, together with the activists, called for 
long-term insurance against possible trial-related side effects. This was based on the 
fact that the impact of tenofovir on HIV-negative people, especially over the long term, 
was unknown; thus, activists thought it wise that the risk taken by participants be offset 
by some kind of long-term insurance protection. Activists demanded 20-30 years of 
medical coverage for all expenses produced by the possible side effects of tenofovir. 
Unfortunately, the NIH funding guidelines permits but does not require the use of NIH 
funds to cover insurance and medical insurance to treat participants suffering from 
trial-related adverse events and, in cases where this is allowed, then such insurance 
must end at the close of the trial. This NIH policy prohibition for health insurance 
coverage brought frustration to the research participants and the activists, and they 
perceived this refusal as a tacit admission that tenofovir might have serious and lasting 
health implications and thus triggered an end to the study. 
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 Compensation to research participants. Above all, the subject of compensation was 
exceptionally problematical as US law does not permit research sponsors to offer free 
medical care or compensation to research participants harmed in clinical research 
studies (Steinbrook, 2006). Though medical care was to be provided to participants 
from the research facility, for the duration of the trial only, it was never clear whether 
potential participants comprehended this and, at the end, there was no delivery of 
medical care after the trial, besides the access to ART for seroconverts through the 
then-fledgling national programme. It was unclear whether the preferential access to 
ART for trial participants was well understood by the trial participants, as access to 
ART was mentioned as a main matter by the activists. Adverse effects of the study 
drug, particularly potential severe long-term ones, became a very important centre of 
interest for the potential study participants. This was so because most of these 
participants were the main source of income for their families, who depended on the 
fitness of the commercial sex workers for work (Bridget G Haire, 2011). 
 
4.1.2 Cameroon 
Cameroon is a former German colony (1884–1914), which later became a United 
Nations mandated territory with part trusted to France and the other part to Great Britain. The 
territory of Cameroon covers approximately 475,650 km², with the country having close to 
4,591 km of land borders and 590 km of coastline along the Atlantic seaboard. Land borders 
include Chad in the northeast, Gabon and Equatorial Guinea in the south, Nigeria in the west, 
the Central African Republic in the east, and Congo (World Health Organization (WHO), 
2016). The country is multi-ethnic, multi-cultural and multi-lingual, with English and French 
(dominant in eight out of ten regions) being the official languages. Cameroon has an estimated 
population of 22 million inhabitants (BUCREP, 2015) 
On September 8, 2001, FHI was visited by Gilead Sciences to discuss the role of 
tenofovir in a research study on HIV prevention and on October 6, 2001, FHI and Gilead visited 
the Bill and Melinda Gates Foundation to share their interest in conducting a tenofovir PrEP 
trial. On November 27, 2001, the Gates Foundation held an ethical consultation with experts 
on the proposal by FHI to test oral tenofovir in a phase III trial in Cameroon, (McGrory, Irvin, 
& Heise, 2009) and in October 2002, one year after the initial PrEP proposal was submitted to 
the Gates Foundation, the sum of US$6.5 million was awarded by the Gates Foundation to FHI. 
This award was a three-year grant for a multinational clinical trial to evaluate the efficacy and 
safety of tenofovir as a method for the prevention of HIV.  
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In January 23, 2003, the Minister of Public Health in Cameroon authorised FHI to carry 
out the tenofovir trial in Cameroon, and in September 2003, formative research began in 
Douala. Specifically, this formative research had three main objectives: 
o Site preparation assessment: This involved the preparation of the site for the 
implementation of the clinical trial and this comprised five components:  
 To identify areas with high HIV transmission and assess the cohesiveness of the 
targeted population of the community,  
 Assess options for community consultations, 
 Assess the processes of informed consent and the approach to be used to ensure that 
the words used in the informed consent booklets were suitable to the local language(s). 
They also had to identify proper communication strategies for the explanation of 
complicated concepts in the consent form (e.g. the use of a placebo) and to explore 
strategies for the evaluation of participants’ understanding, 
 Verify whether FHI’s assumptions about care and treatment were compatible with 
the values upheld by the stakeholders of the community. Identify available resources 
for HIV care and potential referral sites for participants and their families. Obtain 
communities’ input on how to address broader access to care issues, 
 Assess the degree to which stigma was a problem, and its potential consequences, 
and to develop a strategy to decrease the risk of stigmatisation. Devise strategies to 
monitor for social harms throughout the trial and evaluate the existing prevention 
programmes, HIV-risk behaviours and unmet HIV-prevention requirements, to inform 
the guidelines for HIV-risk reduction counselling. 
 
‘Community’ in this context was defined as persons associated with the ‘high-
transmission areas’ in Douala, where the research was to be conducted, and it included 
potential trial participants and partners of potential trial participants. It also included 
local HIV-prevention and care providers and community gatekeepers. 
 
o Acceptability assessment: This entailed assessing the suitability of tenofovir as an 
HIV-preventive intervention amongst potential participants for the trial, their spouses, 




o Research outcomes assessment: This entailed identifying obstacles and facilitators to 
the conversion of the results of the trial for use in HIV-prevention programmes 
(McGrory et al., 2009). 
 
Starting from late September 2003, FHI first held an expert meeting with members of the 
community, with professionals working in the HIV field and with at-risk populations. 
Anecdotal information obtained here was combined with epidemiological information to 
ascertain potential areas of high transmission. Next, the formative research team studied 25 
sites in six areas of high transmission and then carried out 53 detailed interviews. The study 
conducted five focus groups discussions with women at high risk for HIV; community 
members; people living with HIV; health care providers; public health officials; and NGOs 
working with women’s issues or HIV, or both. The same research team embarked on collecting 
onsite participant remarks to find out more about the health beliefs, knowledge of HIV/AIDS, 
the community, past experience with research, attitudes toward prevention research, level of 
comprehension and to substantiate information from the expert meetings (Nyiama, Mack, 
MacQueen, Guest, & Namey, 2006). 
The Protection of Human Subjects Committee, which is the FHI’s IRB, initially 
approved the study in August 2003, requiring a yearly renewal. On December 16, 2003, the 
Cameroon National Ethics Committee approved the study protocol for one year and this 
committee later renewed its approval on December 11, 2004. On April 22, 2004, the study was 
authorised to be carried out in Douala by the Littoral Provincial Delegation of the Ministry of 
Public Health, and the trial commenced enrolment in July 2004 (McGrory et al., 2009). The 
trial was stopped by the Minister of Public Health, Urbain Olangnena Awono, in February 2005, 
spurred on by protests both from within and outside the country. 
The protests were driven by ACT-UP Paris, who collaborated with Réseau Éthique 
Droit et Santé (REDS), an AIDs activist group that is based in Cameroon. These protesters 
underscored their worries with how the study was conducted. Specifically the activists were 
concerned with: 
 The level of HIV prevention counselling offered to participants. They complained 
that there were only five counsellors available to counsel a total of 400 women. 
 The absence of the provision of female condoms (the trial provided only male 
condoms). Participants (sex workers) were provided only with male condoms; it 




 Purported inadequate preparation for the provision of ART. In fact, the informed 
consent documents unequivocally indicated that the trial would not offer ART to 
seroconverts. This position was taken based on the notion that offering ART in a 
context where it was not generally obtainable would represent an undue inducement 
(McGrory et al., 2009). Trial seroconverts were to be sent to existing NGO sources 
for treatment; the ACT-UP Paris activist group portrayed these as overburdened 
with the provision of treatment for 10,000 persons, while 40,000 persons were 
already in need (ACT-UP Paris, 2008). 
 
Besides these essential worries, Mills and colleagues (E. J. Mills et al., 2005) reported 
extensive, incorrect allegations that the investigators were intentionally injecting participants 
with HIV, and or that the tablets themselves contained the HI virus. These allegations came 
from a claim advanced by the ACT-UP Paris activist group, that the offering of insufficient 
counselling for HIV prevention to participants was a back-door approach for augmenting the 
infection of HIV in the cohort. Activists alleged that the FHI investigators deliberately let 
participants become infected and equally offered insufficient counselling, as the 400 
participants were being counselled by only five counsellors (UN Integrated Regional 
Information Networks, 2005). In addition, activists alleged that the volunteers were vulnerable 
participants whose rights were being exploited and that the participants in the trial were not 
fully informed of the risks involved in the trial. 
Another important issue raised was that the majority of these sex workers were 
uneducated and did not have a good mastery of the English language and could only understand 
a small amount of French. Despite this, informed consent forms and protocol documents were 
provided only in English, only one of the two official languages of Cameroon. In addition, 
participants mistook the drug for a vaccine against AIDS and thus became more careless in their 
behaviour and thus more susceptible to the disease. 
Activists and ethicists also argued about the controversial subject of the standard of care 
in randomised trials (Singh, 2004); according to the protocol of FHI, participants who 
seroconverted in the course of the trial were to be offered state-of-the-art ARV therapy, with 
the likelihood of continuing treatment after the close of the trial. The activist groups argued that 
treatment ought to be offered in a similar way as would be offered in developed countries 
Activists argued that, if the primary endpoint of the trial was infection, then counselling 
participants on safe sexual behaviour lessens the probability of discovering an effect. As a result 
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of this, activists alleged that investigators had a conflict of interest between attaining the 
standards of human rights and acquiring scientific data 
Undesirable and incorrect messages were reiterated, and on several occasions, 
overstated in various media spaces. For example, a radio programme reported that the research 
team was giving money “to young girls on tenofovir in an operation (surgery) that will last for 
two hours” (Mack et al., 2010). 
Finally, activists in general supported a wider conception of the term ‘the community’ 
than the FHI understood it during this trial. A wider range of international and national civil 
society groups today regard themselves as stakeholders in the research business. For example, 
activists were amazed to learned that national and local associations of persons living with HIV 
and AIDS were not consulted and were not aware of the ongoing research (McGrory et al., 
2009) . 
As a response to these allegations, the government of Cameroon created an independent 
committee of inquiry to look into the trial, and finally, the Public Health ministry decided that 
the trial could not continue in the absence of frequent reporting and an official authorisation of 
the satellite trial clinic as a study site (Atatah, 2005,February 24). The committee of inquiry 
later proposed that the trial be resumed after the administrators of the trial had addressed the 
issue of reporting and equally obtained site authorisation. However, in July 2005, FHI 
announced that the suspension was too long to permit the trial to continue and hence decided 
to close the trial. In August 2005, FHI announced its decision to close down the Douala study 
site, justifying the decision on the basis that the participants had been off the study drug for 
















RESULTS AND DISCUSSION 
  
 Human participants are frequently involved in health research and because of this, it is 
very important to respect the safety, rights and well-being of these participants, thus ensuring 
that the research is carried out within the best possible scientific rigour so as to generate reliable 
data to inform policies in health. In response to this call, numerous guidelines have been 
established to foster good research practices. Some of these guidelines include: the Declaration 
of Helsinki, the guidelines of the Council for International Organizations of Medical Sciences 
(CIOMS) and the World Health Organization (WHO), and the International Council for 
Harmonization (ICH) Good Clinical Practice (GCP) guidelines. This chapter presents, among 
the different international guidelines, those that discuss the issue of CE, since the focus of this 
thesis is on CE in health research. The chapter further pinpoints within the different 
international guidelines the approaches that were being implemented during the tenofovir trial 
and those that were not being implemented. 
 
5.1 Existing international guidelines and their position on CE 
5.1.1 Nuremberg Code 
 The Nuremberg Code, made up of ten principles, was one of the first ethical guidelines 
on ethical research to be produced. The code was primarily written by jurists in 1947 as a result 
of the Nuremberg trials in which Nazi physicians were accused of shockingly cruel research on 
prisoners in concentration camps in the course of the Second World War. Between November 
1945 and October 1946, an American military tribunal was assembled to listen and examine the 
charges against 23 administrators and physicians of German nationality (Bloxham, 2013). 
During the period of the “Doctors’ trial”, as it was commonly referred to, eyewitnesses 
presented situations of dreadful medical research involving participants involuntarily, the 
greatest number of whom were imprisoned Poles, Jews, Roma and Russians. These participants 
were exposed to exceedingly merciless research, which led to many of them dying, while 
survivors were left with severe scars and other malformations. The judgement decision (August 
19, 1947) comprised a part titled “Permissible Medical Experiments” which became known as 
the ‘Nuremberg Code’ (Nuremberg Code, 1949) and addressed fundamental issues involving 
human participants in medical experimentation. The Nuremberg Code is the basis for many 
successive endeavours for defining and codifying protections for human participants in medical 
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experimentations. The Nuremberg Code does not address the issue of community 
participation/engagement. 
 
5.1.2 Declaration of Helsinki 
 The World Medical Association (WMA) recommendations that guide medical 
practitioners in biomedical research involving human participants were received at the 18th 
World Medical Assembly in Helsinki, Finland, in June 1964 (Rickham, 1964); these are 
commonly referred to as the Declaration of Helsinki. This declaration has undergone seven 
revisions, with the most recent at the October 2013 General Assembly. The document, produced 
by physicians as opposed to jurists (who drafted the Nuremberg Code), is in some ways an 
enhancement of the Nuremberg Code in that it provides more details on the principles listed in 
the Nuremberg Code and offers practical guidelines for carrying out experimentation with 
humans. It also brings a balance between people’s concerns and the benefits to the general 
public (LaFrance, 2007). The Declaration of Helsinki stipulates the information that researchers 
must give to participants prior to obtaining consent. This information includes all anticipatable 
benefits and risks, information that the participant may pull out of the study at any given time 
and lastly, a comprehensive literature of the protocol of the research.  
The Declaration of Helsinki acknowledges the possibility for unintentional compulsion 
that might result from the investigator/participant relationship and suggests that under such 
conditions, an investigator aside from the principal investigator should obtain the consent of 
the participant. One of the key necessities postulated in the Declaration of Helsinki was the 
appointment of independent committees for reflection, observations and guidance on research 
protocols (Basic principle 2) (World Medical Association (WMA), 1964) and, ever since, 
research ethics committees have been set all up over world and remain a key authority 
instrument for human participant research. The Declaration of Helsinki does not address the 
issue of community participation/engagement. 
 
5.1.3 Belmont Report 
 In 1974, the US Congress established the National Commission for the Protection of 
Human Subjects of Biomedical and Behavioural Research in response to the Tuskegee Syphilis 
study. This commission was created to identify the fundamental ethical principles which should 
guide research with human participants and to create guidelines that would ensure that research 
was carried out in conformity with the principles. The National Commission met at the 
Smithsonian Institution’s Belmont Conference Centre in 1976 and from there, successive 
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discussions arose, the end product of which was the creation of a document entitled Ethical 
principles and guidelines for the protection of human subjects of research. This document has 
three sections and is usually referred to as the ‘Belmont Report’(1978) . 
The first section details the limits between research and medical practices. The next 
section institutes three fundamental ethical principles: ‘respect for persons’, ‘beneficence’ and 
‘justice’. The third section offers three requirements for applying the general principles to 
research conduct. These include informed consent, risk and benefits assessment and participant 
selection. The Belmont Report does not address the issue of community 
participation/engagement. 
 
5.1.4 Council for International Organizations of Medical Sciences (CIOMS) 
 In understanding of the situations of developing countries with respect to the application 
of the Nuremberg Code and Declaration of Helsinki, in 1982, the Council for International 
Organizations of Medical Sciences (CIOMS) and the World Health Organization (WHO) issued 
the Proposed international guidelines for biomedical research involving human subjects (2016) 
. These guidelines recognise the supremacy of local concerns in the evaluation of the research 
protocol objectives. For the very first time in an international guideline, the issue of 
compensation being required for persons injured in the course of the research is dealt with. The 
CIOMS guidelines also draw attention to the issue of community engagement in health 
research, denoting in Guideline 7 that research activities must be centred on a continuous 
commitment to sustain community engagement. The focus is on communication of the research 
purpose, design and possible risks and benefits to the individuals and the society as a whole, as 
well as the elicitation of the concerns and preferences of the community. 
 
5.1.5 Federal Regulations – Office for Human Research Protections (OHRP) 
 Since 1966, the National Institutes of Health (NIH) has had a policy concerned with 
protecting human participants in research. That policy did not, however, have any regulatory 
standing until 1974 when the National Research Act (NRA) became operational. Research 
ethics committees were created as part of the NIH policy. The NRA created the commission 
which established the Belmont Report and in reaction to suggestions in this report, in 1981, 
passed legislation codifying the Department of Health and Human Services rules and 
regulations on biomedical research with human participants. The regulations by NIH appeared 
in Title 45, Part 46 of the Code of Federal Regulations (45 CFR 46), with amendments in 1983 
and 1991 (Office for Human Research Protections, 2014). All rules which were approved in 
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1980 pertaining to clinical trials are regulated by the Food and Drug Administration (FDA) in 
21 CFR Parts 50 and 56. The Office for Protection from Research Risks (OPRR) was 
established inside NIH as part of NRA. In 2000, the OPRR was restructured as a Health and 
Human Services department-level agency, with a new name: the Office for Human Research 
Protections (OHRP). 
The regulations (45 CFR 46) consist of four parts. A is entitled the ‘Common Rule’ and 
consists mostly of the regulatory facets of protecting research participants, defining research as 
“a systematic investigation, including research development, testing and evaluation, designed 
to develop or contribute to generalisable knowledge” (Federal Register, 1991). 
The core components of the Common Rule include: requirements for assuring 
compliance by research institutions; requirements for researchers obtaining and documenting 
informed consent; requirements for institutional review board (IRB) membership, function, 
operations, review of research, and record keeping (Code of Federal Regulations, 2009). 
Parts B, C and D of 45 CFR 46 are designed specially to protect pregnant women, 
research with foetal tissue, children and prisoners. Institutional review boards reviewing studies 
that involve these particular participants must pay due consideration to whether they are really 
needed for the research. Unless their involvement is highly relevant to the study, these 
participants will normally be exempted from participating. All grants awarded by the 
Department of Health and Human Services require compliance with 45 CFR 46 or 21 CFR 50 
from the receiving institution. Neither the Common Rule (part A) nor parts B, C or D address 
the issue of community participation/engagement. 
 
5.1.6 The Nuffield Council on Bioethics (NCOB) 
 The Nuffield Council on Bioethics is a self-governing organisation that was created in 
1991 for the examination of ethical issues that arise from developments in biomedicine and 
biology with a focus on supporting the development of public policies and promoting public 
knowledge. When the NCOB identifies an aspect of key ethical concern, it forms a 
multidisciplinary working party, with members who have the relevant know-how to scrutinise 
and report on the concern. Since 1991, the NCOB has been one of the United Kingdom’s 
leading bioethics advisory organisations. It has released more than a dozen reports and 
discussion papers on the ethical scope of several medical and biological technologies. These 
reports have been very influential in shaping public policies and bioethical debates, both within 
and outside of the UK.  
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The NCOB 2002 report does address the issue of community participation/engagement. 
It emphasises the relevance of involving and consenting with the community in the conduct of 
research in developing countries. Paragraph 6.19 states that, “[i]n some societies, it would be 
considered culturally inappropriate for researchers to ask individuals to participate in research 
without consulting the community or permission from community leaders” (Nuffield Council 
on Bioethics, 2002). Paragraph 6.20 further cautions that “to seek consent from an individual 
without seeking assent from leader(s) of the community, or creating public acceptance of 
research, may be considered disrespectful and may harm the relationships within that 
community and between a community and researchers” (Nuffield Council on Bioethics, 2002). 
 
5.1.7 International Council for Harmonisation (ICH) – Good Clinical Practice (GCP) 
guideline (1996) 
The ICH GCP E6 guideline (ICH GCP) was issued in 1996 (International Council for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), June 10, 
1996) and was established by the WHO after consulting with the national drug regulatory 
agencies in developed countries. Its goal was to set internationally acceptable principles that 
can be applied to clinical trials. This is to help provide shared acknowledgement of data between 
concerned countries, which then contributes to the harmonisation process of results. The ICH 
GCP guideline, which is intended to be relevant to all phases of the development of a drug, can 
equally apply to the concept of biomedical research. The ICH GCP guideline does not address 
the issue of community participation/engagement. 
 
5.1.8 Other guidelines positions on community engagement 
 In 2000, UNAIDS put forward a complete set of guidelines for HIV vaccine trial 
implementation, which referenced the participation of the community. Guidance point 5 states 
that: “Community representatives should be involved in an early and sustained manner in the 
design, development, implementation, and distribution of results of HIV vaccine research” and 
this includes the establishment of “a continuing forum for communication and problem-
solving” (UNAIDS, 2000)p. 19). In the revised and enlarged 2007 Ethical considerations in 
biomedical HIV prevention trials, the language was altered with the need for CE to gain 
increased attention:  
 
Guidance point 2: Community participation 
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To ensure the ethical and scientific quality and outcome of proposed research, its 
relevance to the affected community, and its acceptance by the affected community, 
researchers and trial sponsors should consult communities through a transparent and 
meaningful participatory process which involves them in an early and sustained manner 
in the design, development, implementation, monitoring, and distribution of results of 
biomedical HIV prevention trials (UNAIDS/WHO, 2007). 
 
Also in 2007, UNAIDS and AVAC (a global advocacy organisation that is involved in HIV-
prevention research) co-authored the Good participatory practice guidelines for biomedical 
HIV prevention trials (GPP-HIV) (UNAIDS/AVAC, 2007). The GPP-HIV were updated in 
2011 and include guiding principles for the implementation of stakeholder and community 
engagements (UNAIDS/AVAC, 2011). The Community and Stakeholder Engagement 
Workgroup of the Critical Path to TB Drug Regimens (CPTR) worked in partnership with 
AVAC in adapting the GPP-HIV for tuberculosis (TB) research. This collaboration led to the 
releasing of the Good participatory practice guidelines for TB drug trials (GPP-TB) in 2012 
(Boulanger et al., 2013; Critical Path to TB Drug Regimens (CPTR/AVAC), 2012). The 
importance of CE as a cross-cutting ethical issue for TB, malaria and HIV vaccine trials was 
highlighted in a report from a consultation meeting in 2009, a meeting funded by the Ethics, 
Law and Human Rights Collaborating Centre of the WHO/UNAIDS African AIDS Vaccine 
Programme (Mamotte, Wassenaar, Koen, & Essack, 2010). 
Also in 2009, the HIV Prevention Trials Network’s (HPTN) ethical guidance on 
research (Rennie, Sugarman, & HPTN Ethics Working Group, 2009) in Guidance point 3, 
openly addressed CE as an ethical obligation: “In order to ensure that HPTN research is 
appropriate as well as scientifically and ethically sound, relevant communities will be engaged 
in a meaningful process that will help guide the research from protocol development to 
dissemination of results”. 
CE has been clearly integrated into some national guidelines broadly, as well as 
specifically for clinical research and HIV research, respectively. One of such national 
guidelines has been the South Africa’s National Health Research Ethics Council’s Guidelines 
for good practice in the conduct of clinical trials involving human participants (Department of 
Health, 2006). These guidelines recommend that ethics committees require investigators to 
provide plans on consulting with the representatives of the community and also expect 
communities to be involved during the research and in the dissemination of research results. 
The guidelines also remark on the relevance of engaging communities in research, especially 
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when they are considered ‘vulnerable’, and they explicitly demand CE in population-focused 
HIV-prevention research design and conduct (Department of Health, 2006). The guidelines 
further recommend that funders create community advisory groups (CAGs) for research 
conducted at the level of the community (e.g. vaccine trials) as a way to “ensure adequate 
consultation with civil organisations that may exist within affected communities at all phases 
of the trial” (Department of Health, 2006)29). 
 Due to some deficiencies related to the application of these existing guidelines, in 2004, 
Emanuel and colleagues at the US National Institutes of Health (NIH), drawing on the different 
guidelines and principles, proposed an ethical framework for minimising exploitation and 
promoting collaborative partnerships as indispensable to the ethical justification of research in 
low- and middle-income countries (LMICs). Some of these deficiencies included the fact that 
some ethical guidelines could be interpreted in multiple ways, while others appeared 
paradoxical or relied on unspecified but debatable ethical principles (Emanuel et al., 2004). 
 This Emanuel et al. (2004) ethical framework consists of eight key 
principles/benchmarks for the planning and review of biomedical research in LMICs, and these 
have now become accepted and used worldwide. While the different existing guidelines appear 
as official documents for reference in the conduct of biomedical research, it should be known 
that the ethical framework by Emanuel et al. is non-official although it assists researchers in the 
research process. These eight principles/benchmarks include:  
1. Collaborative partnership/community engagement: Collaborative partnerships have to 
be established between the researchers and the community in which the research is being 
carried out as this collaboration will help in ensuring that the research conducted is 
acceptable, offers valuable benefits to the community and is responsive to the actual 
health problems of the community.  
2. Social or clinical significance: All research should be carried out with the sole purpose 
of providing responses to one or more questions of potential social/clinical significance, 
since any research which lacks value provides no basis for the justification of risks to 
the participants.  
3. Scientific merit: Research must be designed and carried out with adequately meticulous 
methods if such research is to be scientifically validated. Planned studies that lack 
scientific validity are unethical. This is because they expose participants to risk in 
research having no potential to generate generalised knowledge.  
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4. Fair selection of study participants: Research participants must be fairly selected in 
accordance with the scientific goals of the study, avoiding redundant involvement of 
vulnerable groups.  
5. Favourable risk-benefit ratio: All research must have a favourable risk-benefit ratio 
that minimises risks to participants and aligns the risks to the potential benefits for 
participants and the value of the obtainable knowledge from the research. 
6. Informed consent: Eligible adults must not be enrolled in research studies if they have 
not been sufficiently informed about the study and they have accepted to take part. For 
research involving incompetent adults and children, informed permission by parents or 
other substitute decision makers, is imperative. 
7. Independent ethical review: To ensure participant protection and public accountability, 
all research studies must obtain eventual and continuous protocol review by a committee 
that is comprised of individuals who are independent of the research.  
8. Respect for recruited study participants and study population: Research must be 
carried out in a way which respects the rights and protects the welfare of enrolled 
participants. 
 
Collaborative partnership is ascertained as the main factor in the ethical framework for 
multinational research developed by Emanuel and colleagues. The respect of a “community’s 
values, culture, traditions, and social practices” is regarded as an important aspect in building 
successful partnerships. Table 3 presents a tabular representation of the different international 
guidelines and their positions on CE. 
 
Table 3: The positions of the different international guidelines on CE 
Source 








“The process must be 
completely collaborative and 
transparent and should involve 
a wide variety of participants 
such as patients and consumer 
organisations, community 
leaders and representatives, 
relevant NGOs and advocacy 
groups, regulatory authorities, 
This was not 
applied here as 
the was no CAB 
creation as well as 
advocacy groups 
as required. 
This was not 
applied here as the 
was no CAB 
creation as well as 




government agencies and 
community advisory boards.” 
“The community should 
participate when feasible in the 
actual discussion and 
preparation of the research 
protocol and documents.” 
Members were 
never involve in 
the preparation of 
the study protocol 
Members were 
never involve in 
the preparation of 
the study protocol 
“Engagement at the earliest 
opportunity. Before a study 
commenced, the community 
from which participants will be 
recruited should, when 
feasible, be consulted about 
their research priorities, 
preferred trial designs, 
willingness to be involved in 




after the study 
protocol and 
designed had 
been agreed upon 
by the research 
team. 
Members were 
only engaged after 
the study protocol 
and designed had 
been agreed upon 
by the research 
team. 
“Community engagement 
should be an ongoing process, 
with an established forum for 
communication between 
researchers and community 
members.” 
The community 
was only engaged 
once during 
formative 




was only engaged 
once during 
formative research 
and not continuous 
as recommended 
“Community members should 
be invited to assist in the 
development of the informed 
consent process and documents 
to ensure that they are 
understandable and appropriate 
for potential participants.” 
Members never 
involved in the 
development of 
any working 
document for the 




involved in the 
development of any 
working document 
for the study with 
the informed 
consent inclusive 
“Any disagreements that may 
arise regarding the design or 
conduct of the research must 
be subject to negotiation 
This was not the 
case as concerns 
with regards the 
research design 
This was not the 
case as concerns 




between community leaders 
and the researchers.” 
could not be 
adjusted as the 
study protocol 
had already been 
agreed upon 
could not be 
adjusted as the 
study protocol had 
already been 
agreed upon 








“Consultation is required with 
the community before 













prior to project 
commencement 
“Permission from the leader(s) 
of the community is required 
before any research is 





obtained from the 
community 






obtained from the 
community leaders 
prior to project 
commencement 
“A comprehensive care 
package should be agreed upon 
through a 
host/community/sponsor 
dialogue, which reaches 
consensus prior to initiation of 
a trial.” 
A comprehensive 
care package was 
never agreed 
upon given room 
for 
misunderstanding 
on what this 
ought to be. 
A comprehensive 
care package was 
never agreed upon 
given room for 
misunderstanding 







“To ensure the ethical and 
scientific quality of proposed 
research, its relevance to the 
affected community, and its 
acceptance by the affected 
community, community 
representatives should be 
involved in an early and 
sustained manner in the design, 
development, implementation, 
and distribution of results of 
HIV vaccine research.” 
Community 
members were 
not involved in an 
early and 
sustained manner 
as they were only 
involved after 
protocol design 
had been done 
and the absence 
of CABs implied 




members were not 
involved in an 
early and sustained 
manner as they 
were only involved 
after protocol 
design had been 
done and the 
absence of CABs 





“Involvement of community 
representatives should not be 
seen as a single encounter, nor 
as one-directional. The 
orientation of community 
involvement should be one of 
partnership towards mutual 
education and consensus-
building regarding all aspects 
of the vaccine development 
programme. There should be 
established a continuing forum 
for communication and 
problem-solving on all aspects 










only engaged once 
as against the 
continuous 
approach requested 
“Members of the community 
who may contribute to a 
vaccine development process 
include representatives of the 
research population eligible to 
serve as research participants, 
other members of the 
community who would be 
among the intended 
beneficiaries of the developed 
vaccine, relevant non-
governmental organisations, 
persons living with HIV/AIDS, 
community leaders, public 
health officials, and those who 
provide health care and other 
services to people living with 
and affected by HIV.” 




benefit from the 
developed 
vaccine as it was 
never disclosed or 
any formal 
agreement upon 
None of the 
community 
members were 
destined to benefit 
from the developed 
vaccine as it was 











“To ensure the ethical and 
scientific quality and outcome 
of proposed research, its 
relevance to the affected 
community, and its acceptance 
by the affected community, 
researchers and trial sponsors 
should consult communities 
through a transparent and 
meaningful participatory 
process which involves them in 
an early and sustained manner 
in the design, development, 
implementation, and 
distribution of results of 




never consulted in 
a sustained 
manner and were 
never also 
engaged early in 
the design and 
development of 




never consulted in 
a sustained manner 
and were never 
also engaged early 
in the design and 
development of the 
study protocol as 
recommended 
“The nature of community 
involvement should be one of 
continuous mutual education 
and respect, partnership, and 
consensus-building regarding 
all aspects of the testing of 
potential biomedical HIV 
prevention products. A 
continuing forum should be 
established for communication 
and problem-solving on all 




process was never 
continuous given 
the absent of 
CABs which a 




process was never 
continuous given 
the absent of CABs 




“As more groups and people 
define themselves as part of the 
interested community, the 
concept needs to be broadened 
to civil society so as to include 
advocates, media, human rights 
organisations, national 
institutions and governments, 
as well as researchers and 
community representatives 
from the trial site” 
The aspect of 
community here 
appeared very 
limited as it did 
not include civil 
societies and 
activist groups. 
The aspect of 
community here 
appeared very 
limited as it did not 
include civil 
societies and 










“In order to ensure that HPTN 
research is appropriate as well 
as scientifically and ethically 
sound, relevant communities 
will be engaged in a 
meaningful process that will 
help guide the research from 
protocol development to 
dissemination of results.” 
Community were 
never engaged 
from the protocol 
development as 
the community 
was only engaged 




from the protocol 
development as the 
community was 




good practice in 
the conduct of 





“Studies require active 
community participation in 
both the design and the 
monitoring of the intervention 
is to be applied to a 
population.” 
Community were 
never engaged in 
the design of the 
study 
Community were 
never engaged in 
the design of the 
study 
 
 From Table 3, it can be noticed that there is no reference to the Nuremberg Code, the 
Declaration of Helsinki, the Belmont Report, the Federal Regulations – Office for Human 
Research Protections (OHRP) and the ICH-GCP guideline (1996). This is because nothing is 
mentioned in these guidelines about the concept of community engagement in research. 
Secondly, the table does not mention the Emanuel et al. (2004) guidelines which specifically 
address the issue of CE. This is because the table seeks to capture just pertinent guideline 
phrases that give specific instructions on how community engagement should be implemented 
throughout the conduct of a study, which was not the case for Emanuel et al. guidelines.  
 Out of all the current guidelines, the CIOMS guidelines offer the clearest directives, as 
far as implementing CE is concerned. Many guidelines require that representatives and leaders 
of communities, advocacy groups and relevant NGOs be included in the CE process (CIOMS, 
2016; UNAIDS, 2000; UNAIDS/WHO, 2007). Noteworthy from the tenofovir trials in 
Cambodia and Cameroon was that this requirement was not taken into consideration, as can be 
seen from the protests that led to the closure of the two sites: activist groups who complained 
(amongst other things) of having been left out in the process.  
Many of these guidelines recommend that the community partake in the discussion, 
preparation and design of the protocol of the research (CIOMS, 2016; DOH, 2006; Rennie & 
Sugarman, 2009; UNAIDS, 2000; UNAIDS/WHO, 2007) but again this was never done in 
Cambodia and Cameroon; the communities were consulted only after the study protocol had 
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been designed and ethical clearance had been obtained for the study. In addition, it is also 
required that the community should be engaged at the earliest opportunity during the conduct 
of the study (CIOMS, 2016; UNAIDS, 2000; UNAIDS/WHO, 2007), but this was not the case 
for either study.  
The guidelines also recommend that CE should be an ongoing process (CIOMS, 2016; 
UNAIDS, 2000; UNAIDS/WHO, 2007). In the tenofovir trials, FHI never set up a CAB or any 
other structure for ongoing community involvement. CIOMS (2016) advises that any 
disagreement that may arise with regard to the research design or conduct must be subjected to 
negotiation between community leaders, but this was not done, as disagreements between 
researchers and potential participants were never addressed prior to the commencement of the 
study.  
Finally, while the NCOB (2002) requires that the ‘care package’ be agreed upon prior 
to initiation of a trial, this appeared not to have been fulfilled, as this was one of the reasons for 
the protest by the activist groups in both countries. It should be noted, however, that the 
requirement that consultation with the community before engaging with the individuals and 
obtaining permission from community leaders prior to the commencement of the study (NCOB, 
2002) was very much respected on both sites. 
 
5.2 Concerns about how community engagement is practiced in some 
cases/projects 
 In spite of very clear objectives directed to the production of socially responsible 
knowledge, CE practices are not yet innately democratising, as engagement in health research 
is at times used for instrumental gains  – ensuring smooth research operations, increasing 
consent and study enrolment, gaining community buy-in – instead of achieving a wider 
revolution in the politics and power dynamics of research. 
The researcher included this section in the research so as to demonstrate that poor CE 
is not only noticeable in the tenofovir trials but that it cuts across most health-related research 
studies requiring CE. Below are some shared characteristics and concerns in the way 
community engagement is practiced in some cases. 
The first concern centres on the late engagement of the community in research projects. 
Most researchers only engage the community after the ethical and administrative clearance for 
the study have been obtained. International guidelines from CIOMS, the Nuffield Council on 
Bioethics and the National Institute of Allergy and Infectious Diseases have all emphasised the 
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significance of early CE, as this permits the local population to express their views on the 
research and facilitates the researcher to develop culturally appropriate policies geared towards 
the study. 
Community engagement requires a broad dialogue with main stakeholders that should 
commence long before the implementation of the research study, and discussions with 
community leaders and members should dwell on topics such as the protocol formulation, 
design of the study, methodology of the study, timelines and plans for the implementation of 
the study, and the potential risks for participants.  
This form of community dialogue is very important for several reasons: 
 First, it provides communities with the opportunity to share opinions on the design 
of the study. Sharing their perspectives helps to reduce the challenges that might be 
related to the recruitment and retention of study participants (2012).  
 It facilitates the community’s ownership of the processes of the research and its 
outcomes. This helps to expedite the translation of research findings into action, a 
regular challenge affecting several research ventures (Barkin & Schlundt, 2011). 
 It promotes the comprehension of the research concepts and lessens myths and 
therapeutic misconceptions centred around the research (Folayan, Mutengu-
Kasirye, & Calazans, 2009; Miller et al., 2010).  
 It reinforces the process of informed consent via the dissemination of information 
on research risks, benefits and goals.  
 It equally helps to inculcate the respect of social norms and practices of potential 
volunteers (Kamuya, Marsh, Kombe, Geissler, & Molyneux, 2013; 
UNAIDS/AVAC, 2011).  
 Finally, in some circumstances, community dialogues are required to negotiate and 
reach consensus on the standard-of-care and prevention packages for participants 
of the study. This is so because, most times, views about these may differ between 
trial volunteers and researchers (Strauss et al., 2001).  
 
When researchers carry out community dialogues, they should expect that some elements of 
the design of the study might be considered undesirable or unethical by members of the 
community and thus be ready to negotiate and correct any potential differences that dissatisfy 
members of the community. One of the key motives for the early stopping of the tenofovir trials 
was that such discords between the potential participants and researchers were never resolved. 
This process of active CE before, during and after research helps in promoting respect for the 
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community, and in strengthening credibility and trust of researchers (Diallo et al., 2005; 
Kamuya et al., 2013); furthermore, it gives the community a sense of ownership and augments 
their interest in the process of the research (Kamuya et al., 2013). Early engagement is a vital 
component if one wants to achieve meaningful engagement. 
The next concern raised in the way community engagement is done in some cases is 
that, even after the researchers engage very early with the community on the conception of the 
protocol, the inputs of the community members are not often taken into consideration or 
inserted into the protocol design. Limiting engagement to an exercise of consultation without 
the concession of power to lay people, ‘tokenism’ on the part of researchers, or failure to act on 
the community’s propositions means that engagement can prove a disheartening encounter for 
certain members of the community and might eventually result in participation withdrawal. 
Evidence from a number of studies (Bickerstaff & Walker, 2005; Chau, 2007; Cole, Hickman, 
& McCoulough, 2004) thus suggests that people are less likely to find CE a positive practice 
where consultation is the principal approach used by experts. This is because, in this method, 
no real power to effect change is relinquished to the members of the community. 
Another concern in the way community engagement is done in some cases is that the 
community is only engaged during the early stages of the study and, as the research continues, 
there is no further discussion and engagement with the community members. Communities 
need to be engaged throughout the life of a research study and not only during community 
meetings when participant recruitment is ongoing, and then again during results dissemination, 
as this does not constitute meaningful CE. 
Moreover, there is concern about the nature of stakeholders included during community 
engagement. Many times, the government is left out in this very important exercise, and the 
researchers focus just on the community of concern. Government appears to be the least 
engaged and least informed though it plays a vital part in regulations. The engagement of the 
national government facilitates consultations about the design and protocol of the research. 
Negotiations between the sponsor and the government are also critical in ensuring future access 
to developing therapies at affordable prices, when needed (Milstien & Kaddar, 2006), and such 
negotiations are properly made during the design of the study through the memoranda of 
understanding signed between the both parties. 
Another key concern in the way community engagement is done in some cases is at the 
level where research protocols are conceptualised. In the discipline of international research, it 
has been shown that the conceptions for research are mostly established by the partners from 
the north, with partners of the south only acting as collaborating investigators. These southern 
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partners are engaged as an effort to “build their capacity to learn something useful to science 
and/or practice in the north” (Engel & Keijzer, 2006, p. 16). 
Finally, a concern with the way community engagement is done in some cases is that 
most research studies engage the community in a rush and do not give ample time for the 
community to receive and assimilate the information they are given by the researcher; the 
researchers also do not give the community enough time to reflect on the information and give 
their feedback and proposals on certain modifications to the protocol at the time of conception. 
This has many potential repercussions.  
There are several studies that have ended in failure, like the ones on the tenofovir trials 
in Africa and Southeast Asia, as a result of rushing the CE process. The community initially 
agreed to participate but then realised as the study progressed that the explanation was not very 
clear at the beginning, which means there was not enough time invested in engagement with 
the community. Community engagement is often a very lengthy process that can be influenced 
by time constraints, finances, and resources (Israel et al., 2006). Researchers most often only 
start to engage the community after they have obtained approval for the study to begin. 
Sometimes, the time between obtaining ethics committee approval for the protocol of the 
research and commencing the implementation of the research is too limited; this may render 
impracticable and unattainable the extensive community consultation required to constitute 
reasonable dialogue between the communities and researchers.  
 
5.3 CE as practiced by both trials: Deviating from the international guidelines 
requirements 
 FHI was under serious pressure from the public health and scientific communities to 
start the trials quickly, as a mutual sense of urgency existed to look for a strategy for HIV-
infection prevention in women. Some FHI researchers agreed that the relative speed with which 
the research was designed and developed had an impact on the degree of community preparation 
and the degree to which formative research findings could be integrated into the processes of 
the trial (McGrory et al., 2009). A wide range of organisations and persons with different 
standpoints remarked that the process of developing and implementing the tenofovir PrEP trials 
was hasty (McGrory et al., 2009). The urgency to start the trial was motivated at least partially 
by the potential that tenofovir appeared to have to provide another method for the prevention 
of HIV infection. The need for a new method for HIV prevention was critically important given 
that the development of the other biomedical interventions for HIV prevention, like the 
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microbicides and vaccines, were experiencing some challenges. Nevertheless, this sense of 
urgency reduced the time to properly prepare, consult and involve the community before the 
commencement of the clinical trial (McGrory et al., 2009). 
The approach by FHI to community consultation in Cameroon entailed the carrying out 
of qualitative research in the community of the trial site. FHI defined the ‘community’ as the 
women who were potential participants in the trial and the main actors around them such as 
their families and partners, policymakers, and AIDS and health care providers in the Douala 
areas where the women worked and lived. This approach was intentionally designed by FHI 
and its partners to allow them get, first hand, the points of view of the actual and potential trial 
participants.  
However, this approach had a problem because, in this situation, these women at high 
risk for HIV were never well ‘structured’ or represented (in terms of in a recognised and 
registered legal organisation or association), and other organisations which might have 
represented the interest of the women did not surface throughout the preparatory work. The 
researchers used this approach because they thought that it was wise for these potential female 
participants to speak for themselves and that they could act as their own activists. It was later 
acknowledged by one of the researchers that this might have been very unrealistic (McGrory et 
al., 2009) . Thus, it is noted that FHI never engaged in a wider civil society or stakeholder 
consultative process and never put in place a CAB or other framework for continuous 
community involvement in the trial implementation. 
Another issue raised by the tenofovir trials was: What comprises an appropriate and 
meaningful community involvement and consultation? The decision by FHI to use formative 
research as their only form of community consultation in the trial proved to be problematic. 
While formative research might have offered a methodological technique into gaining 
understanding of the preferences and views of the potential participants, it was incapable of 
meeting the wider community’s need for dialogue or provision for an assembly for addressing 
the problems raised. The total absent of CABs, or other official structures, implied that no 
system was put in place for continuous discussion or resolution of conflicts when hurdles 
emerged. Furthermore, since FHI prioritised data integrity, and had guaranteed participants of 
confidentiality during the formative process, they were unable to disclose to the activists who 
had and had not been consulted in this process. This made the activists question the process 
even more. 
In the two trial countries, the processes of community consultation and outreach were 
undertaken after the development of the protocol and the decision to carry out the research had 
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been reached. Community consultation was conceived as a dialogue on how to carry out the 
research rather than on where or whether to do the research in the first instance. The activists 
alleged that the organisation of community ‘consultation’ or ‘advisory’ processes after the 
development of the research protocol was not meaningful, as this runs contrary to the various 
established international guidelines on health research. 
From our findings above, it could be observe that the study based her argument on the 
theory of social justice using the ladder of citizen participation by Arnstein (1969). From the 
findings it is illustrated that the types of engagement used here were those identified by Arnstein 
to be near the foot of this ladder (weaker forms of citizen engagement) of participation which 
comprises information dissemination about the planned research. The researcher’s interest here 
was to advocate on the social justice perspective, which is founded on empowerment of the 
community members, which is required for genuine and meaningful engagement and which 























CONCLUSION: LESSONS LEARNT FROM THE TENOFOVIR TRIAL 
 
In the Cameroon case, the criticisms raised during the tenofovir trial comprised of: 
insufficient numbers of study staff; the provision inadequate information about risks to 
participants; insufficient access to care for seroconverts; and an unethical design of the study, 
where participants “were being used as guinea pigs to promote the interest of the drug’s 
manufacturers” (Stone, Stones, Saxena, & Chandhiok, 2005, December 5-6). In particular, the 
inadequate community involvement was emphasised. 
In the Cambodia case, advocates contend that it was improper for western interests to 
take advantage of commercial sex workers for an investigational drug trial, particularly in a 
poor country like Cambodia. They went further to ask why they could not conduct the trial in 
high-risk populations in Europe and the US. Activists even blamed the researchers for providing 
insufficient HIV-prevention counselling in order for the study to attain good results. The use of 
placebo pills created some misunderstanding and misrepresentation, as the researchers were 
criticised for giving ‘dummy pills’ to some women. Activists demanded medical insurance 
coverage to trial participants for trial-related injuries. This insurance coverage was to span 
between 30 and 40 years. Lastly, activists highlighted the inadequate involvement of the 
community in the planning of the study. Properly involving the community would indeed have 
been one tool which, used effectively and efficiently, may have been capable of resolving most 
or even all of the problems noted (Stone et al., 2005, December 5-6). 
Given this missed opportunity, this chapter discusses some of the lessons that can be 
learned from the premature closure of the tenofovir trials that could help other trials to do better 
next time. 
 
6.1 Involve stakeholders in the development of the protocol 
 In both countries, community outreach and consultations only took place after the 
protocol development and the decision to conduct the study had been made. The first lesson is 
that researchers should involve community and national stakeholders in the development of the 
protocol. They should seek critical inputs during the trial design, a stage where changes could 
still be incorporated. Consulting with civil societies after the protocol has been developed will 




6.2 Expand outreach efforts 
 Outreach efforts have to go beyond the immediate geographic surrounding of the trial, 
to involve provincial, national and perhaps international collaborators. Activists were shocked 
to know, for instance, that local and national organisations of persons living with HIV and AIDS 
were not aware of the research and were never consulted (Forbes & Mudaliar, 2009; McGrory 
et al., 2009). 
 
6.3 Consultation rather than formative research  
 While very important, it was not right for FHI to substitute other open processes of 
consultation with formative research. They included substantial formative research as a means 
of systematically gathering community inputs in order to help inform the design of the trial, and 
more significantly, to inform how the results of the trial could contribute to effective and 
adequate prevention interventions. Rather, they should have gone for a consultative process 
with the local organisations, civil societies, targeted community and potential participants, 
which entailed gathering all the elementary materials required for the design of the study 
protocol. It should be known, however, that this consultative process is seen to have taken place 
between FHI and the Bill and Melinda Gates Foundation on the designing of the proposal and 
also with the Gates Foundation and experts on the ethics of the proposal by FHI. The intention 
of the researcher here is not to discard formative research as a tool for engaging the community 
but rather to acknowledge the tool and point to its limitation of meeting the wider community’s 
need for dialogue or provision for an assembly for addressing the problems raised by the 
community 
 
6.4 Mechanisms for dealing with issues 
 Trials need specific procedures and processes for dealing with enquiries, queries and 
grievances. Ideally, this mechanism should involve an informed impartial actor who has 
sufficient facts, documentation, and access, for instance, a CAB or community liaison. This 
structure could receive and elevate the community concerns, as well as facilitate 
communication to ensure that questions and concerns raised by the community members are 
adequately responded to, and in a timely manner. It is noted from the study that the absence of 
an appropriate platform where disagreements between researchers and potential participants 
could be discussed and resolved was highlighted as one of the main reasons for the ending the 
tenofovir trials. Events in both countries highlighted the crucial importance of researchers 
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heeding the inputs obtained from members of the community, participants and other 
stakeholders, in order to deal with their trial-related concerns. The experience made clear that 
controversy in the community undermines a trial as surely as scientific setbacks. 
 
6.5 Create mutual frameworks 
 It is also learned from this study that there is a need for researchers, activists and 
governments to create a mutual framework for future collaboration, acknowledged standards 
and practical methods for engaging the community. The Good Participatory Practice guidelines 
developed by UNAIDS and AVAC provide a worthy initial step, and efforts to establish 
whether these guidelines could be made prescriptive for HIV-prevention trials ought be 
encouraged. 
 
6.6 Educate communities on research processes 
 Mechanisms should be put in place for ensuring that communities obtain a broad 
understanding on what clinical trials are and on the different processes involved. This would 
permit community members to be well informed to participate in dialogue and negotiations 
about a particular trial. Communication strategies should be designed with the main intention 
of gaining a mutual comprehension between the communities and the researchers, each of 
whom might differ in interpretations and expectations. These strategies must clearly 
acknowledge that the usage of scientific language is not always the ‘right’ way to discuss 
research. More so, being uneducated/illiterate should not equate to an incapability to understand 
and criticise scientific procedures.  
Trials with greater success rates, for example, the Navrongo Community Health and 
Family Project (CHFP) in Kassena-Nankana Ghana (Binka et al., 1995), the Majengo 
Observational Cohort Study (MOCS) based on disadvantaged female sex workers in Nairobi, 
Kenya (Bandewar et al., 2010), an epidemiological investigation of some 7-12 year olds in 
South Korea, and an Autism Spectrum Disorder (ASD) detection program for 18-36 month old 
Zulu-speaking children in South Africa (Grinker et al., 2012), are those that permit both 
community stakeholders and researchers to share ideas amongst themselves on prime research 
concerns, as well as on how best to carry out the trials. The community that is treated and 
respected as a partner, instead of as a ‘research participant’ supplier, is likely to be more 
supportive of a planned research study.  
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Although the process of CE cannot absolutely guarantee a collaboration that is free of 
disagreement or free of substantial differing opinions (Newman, 2006), it has been proven that 
productive discussions with community stakeholders can lead to benefits for both the researcher 
and the communities. Examples of this come from a study on the locally appropriate standard 
of care in the context of a phase III vaginal microbicide trial in Mwanza City, northwest 
Tanzania (Vallely et al., 2009), a multicentric clinical trial in Mexico to evaluate the efficacy 
of the Human Papilloma Virus (HPV) vaccine in young men who have sex with men (MSM) 
(Gutiérrez-Luna et al., 2009), and the breastfeeding, antiretroviral, and nutrition (BAN) study 
which is an unblinded clinical trial in Lilongwe, Malawi, focusing on the safety and efficacy of 
antiretroviral and nutritional interventions to reduce mother-to-child transmission of HIV 
during breastfeeding (Corneli et al., 2007). 
Discussing with the community stakeholders can help in refining the procedures for the 
study to suit the local situation. This will go a long way towards maximising the research results 
(Corneli et al., 2007; Gappoo et al., 2009; Gutiérrez-Luna et al., 2009; Vallely et al., 2009) and 
may lead to more effective participant recruitment and enrolment approaches, enhanced rates 
of retention and sturdier adherence to the study. CE necessitates broad discussion with 
important stakeholders and should commence before the implementation of the trial. Discussion 
should focus on issues like the design of the study, how the therapies or vaccines should be 
handled, plans and timelines for the implementation of the study, potential risks to the 
participants of the trial, as well as on how state powers could be involved in the designing and 
execution of the trials in a manner that protects the study participants’ rights (Folayan et al., 
2015). 
 
6.7 Use flexible means to work with communities 
 Another important lesson from these tenofovir trials is that, besides the respect for the 
highest ethical and scientific standards, it is also very important for researchers to work directly 
with the community through various flexible means like the local ethical review boards and the 
CABs, which work as a surrogate for the community. The absence of CABs in both studies 








6.8 Allow sufficient time for community engagement 
 Another important lesson learnt is that researchers should provide sufficient time and 
resources for CE, as engaging with community stakeholders in an iterative and collaborative 
way entails a significant investment. Talking about the priorities of a research study and trying 
to determine the best strategies needs time, effort and financial support, and so institutions and 
sponsors must be ready to finance activities that can develop the conduct of a trial and lay the 
foundation for constructive partnerships in the future (Miller et al., 2010). The urgency of the 
HIV-prevention research must be continually balanced against the apparent cost-cutting 
measure of proceeding too quickly. HIV-prevention trials demand substantial and prolonged 
engagement with the community and national stakeholders prior to the initiation of a trial 
(Forbes & Mudaliar, 2009) . 
CE is gradually being acknowledged as an important constituent of the ethical conduct 
of biomedical HIV-prevention trials, and the Good participatory practice guidelines in 
biomedical HIV prevention trials (GPP) (UNAIDS/AVAC, 2007) provide the primary series of 
global guidelines to outline in-depth steps to ensure appropriate CE within the framework of 
biomedical HIV-prevention trials. The GPP guidelines are designed for implementers and trial 
funders, and they pinpoint key principles for the basis of relationships between community 
stakeholders and trial entities; for example, they include principles such as transparency, 
research literacy, respect, and ethical and scientific integrity. The GPP guidelines are 
sufficiently broad to deal with the differences in trial sites around the world but explicit enough 
to provide an appropriate outline to ease successful implementation of main activities (Miller 
et al., 2010)  
The GPP are based on the same ethical principles of transparency, accountability, 
respect and beneficence that underlie all good clinical practice; however, a distinctive feature 
of the GPP guidelines is that they can be used as an instrument for assessing efficient 
collaborative procedures by trials sponsors, researchers and community stakeholders (Miller et 
al., 2010). 
The speed and the level of sponsoring at which research is presently carried out preclude 
most research associations from having either the resources or the time to participate in training 
activities. However, developing the host community’s research literateness, (typically from the 
base up) is very important in ensuring their capacity to engage efficiently with the process of 
the research (Forbes & Mudaliar, 2009). As the GPP guidelines point out, devoting the effort 
and time needed to engage the trial host community “through genuine, transparent, meaningful 
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participatory processes” is not only an ethical obligation but also an essential contributor to the 
research quality (UNAIDS, 2007). 
 
6.9 Plan for adequate funding 
 Another important lesson is that sponsors and funders of projects should allocate 
adequate funding for intensive community engagement activities, as it is very costly to properly 
engage the community in every stage of the project. The more time it takes to engage with the 
community, the more cost this entails (D. Burns, Heywood, Taylor, Wilde, & Wilson, 2004). 
Most funders shy away from meaningful CE because of this additional cost involved. 
 
6.10 Need for continued engagement between all stakeholders 
 Lastly, the PrEP trials in both countries are case studies of clinical trials that were 
reviewed and approved by several ethics committees, but later found undesirable by certain 
community stakeholders (Miller et al., 2010). Experiences from these trials advise that it can 
no longer be assumed that all planned research studies that require wide-ranging community 
recruitment should be executed exactly as established by both the researchers and IRB, with the 
exclusion of the community in concern. The right case scenario will be for the communities, 
together with the researchers and IRBs, to work together to determine whether a specific study 
is suitable or not at a certain time and location. 
 
6.11 Conclusion 
 In conclusion, the cost of the lack of CE in the tenofovir trials was both financial and in 
terms of lost opportunity. Limited resources for exceedingly costly public-interest health 
research were wasted, and reputations of individuals, organisations and institutions were 
damaged. Other independent observers and researchers even interrogated the trustworthiness 
and rightfulness of research on new HIV-prevention technologies itself, and animosity was 
fostered among AIDS community stakeholders, all of whom express a profound pledge to work 
to end the epidemic. In addition, the early stopping of the trials was a strong message conveyed 
to potential government allies that backing for clinical trials could be scandalous and might 
even be an incitement for political disaster. Moreover, maybe most embarrassingly, the research 
company lost credibility among trial participants and communities who had every historic 
motive to be cynical about drug research studies and their benefits, yet at the same time badly 
needed the new HIV-prevention approach. 
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Maybe the most significant lesson to be acquired from these experiences is that 
government authorities, study community members, activist groups, investigators, sponsors and 
participants must enthusiastically and genuinely engage at all trial stages. This is to ensure that 
the study is carried out in a way that is respectful and beneficial to the participants without 
taking away the scientific validity of the study. 
Given these developments, it is hoped that researchers will embrace this new direction 
(meaningful community engagement rather than just superficial community engagement) as 
one potential way to enhance trial successes and improve the ethical conduct of their research. 
It will be wrong to conclude from this research that genuine and meaningful CE may 
altogether totally address the concerns raised during the two trials and that CE is the only 
remedy required for hitch-free clinical trials. Conversely, what this research seeks to 
demonstrate or argues is that, CE could go a very long way towards averting several of the 
probable glitches that could otherwise occur without meaningful and genuine CE measures and 
mechanisms being put in place. It appears curious to an independent observer that researchers 
and funders are willing to spend millions of dollars on the protocol design, building of facilities, 
clinical training, product development, etc., but leave the core processes of CE mainly to trial 
and error.  
CE must be regarded not only as an ethical requirement but also as a prerequisite, which 
helps to avoid future conflicts and problems that might lead to early closure of a trial. It should 
be known that nobody wins when a trial is discontinued for reasons that are non-scientific. For 
everyone to win in a research study of this magnitude, the researcher suggests that such 
regrettable situations in research studies could be prevented if all research stakeholders spend 
the appropriate resources and time required to develop the kind of common trust on which 
collaborative partnerships can be founded. As established by the tenofovir trials, failure to 
genuinely and meaningfully engage with the community might come at significant scientific 
cost, but early and continued CE can stop this from occurring. 
From the above analysis, the researcher’s quest to demonstrate how inadequate CE 
might come at considerable scientific cost, whereas early, sustained and meaningful CE could 
contribute greatly to research through the understanding of  the root causes of the early stop of 
the trials through the answering of three main questions proof useful in addressing the great 
concern of rethinking CE in health research. Specific questions aimed at understanding the 
complexity that surrounds the concept of “community”, the detailed procedures used for 
engaging the different populations helped in generating useful insights and lessons for future 
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researchers and every stakeholder in the research domain on the appropriate approach to adopt 
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